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Abstract 
The current study examined the relationship between illness invalidation and shame in a 
sample of 168 adults with myalgic encephalomyelitis/chronic fatigue syndrome. Based 
on review of existing qualitative research, it was hypothesized that there would be a 
significant positive relationship between perceived illness invalidation and experiences 
of state shame. Additionally, in light of the Stress Buffering Model, it was hypothesized 
that perceived social support would moderate the relationship between illness 
invalidation and shame. Results indicated that illness invalidation in the form of lack of 
understanding significantly correlated with experiences of shame. Hierarchical multiple 
regression revealed that perceived social support did not, however, significantly 
moderate the relationship between state shame and illness invalidation in the form of 
lack of understanding. 
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Chapter One 
Overview 
Myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome 
(CFS), affects an estimated 2.2 million Americans (Bierl et al., 2004). The etiology of 
ME/CFS continues to be poorly understood and is likely complex (Bierl et al., 2004). 
Existing research suggests the involvement of inflammatory processes (Fulle et al., 
2000; Maes, Mihaylova, Kubera, & Bosmans, 2007; Pall & Satterlee, 2001; Richards, 
Roberts, McGregor, Dunstan, & Butt, 2000), alterations in gene expression (Light et al., 
2011), immune dysfunction (Maes, Twisk, Kubera, & Ringel, 2012; Masuda et al., 
2002), involvement of the hypothalamic-pituitary-adrenal axis  (HPA; Cleare, 2004; 
Johnson & DeLuca, 2005; Van Den Eede, Moorkens, Van Houdenhove, Cosyns, & 
Claes, 2007), and altered levels of progesterone (Pearson Murphy, Abbott, Allison, 
Watts, & Ghadirian, 2004).  Patients experience debilitating fatigue, sleep dysfunction, 
post-exertional malaise, slowed cognitive processing, hypersensitivity to sensory 
stimulation, and other symptoms (Carruthers et al., 2003; Fukuda et al., 1994). 
Despite physiological abnormalities in ME/CFS, the disorder is frequently met 
with challenge, doubt, and suspicion from medical and lay persons (Bayliss et al., 2014; 
Travers & Lawler, 2008). Individuals with ME/CFS have reported experiencing illness 
invalidation by having their illness experiences discounted, minimized, or dismissed by 
medical professionals and significant others (Johnson & Johnson, 2006; Larun & 
Malterud, 2007).  
Further, individuals with ME/CFS have reported feelings of shame associated 
with invalidation of their symptoms (Larun & Malterud, 2007). In qualitative research, 
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patients have sometimes attributed their feelings of shame to medical professionals and 
others expressing the idea that ME/CFS was “all in their heads” (Clarke & James, 2003, 
p. 1390). Patients with ME/CFS have also indicated that experiences of illness-
invalidation and shame led to choosing to isolate from their previous social circles 
(Clarke & James, 2003).  
The Stress Buffering Model proposes that social support counteracts threats to 
self-concept during periods of elevated stress (Cohen & Wills, 1985). Existing research 
appears to support the Stress Buffering Model, with evidence of the emotional benefits 
of social support to patients with health concerns indicated across multiple studies (e.g., 
Demange et al., 2004; Kool et al., 2012; Nenova, DuHamel, Zemon, Rini, & Redd, 
2013; Zabalegui, Cabrera, Navarro, & Cebria, 2011). Within the current study, the 
Stress Buffering Model provides a framework for examining the ameliorative role of 
social support in reducing the shaming effects of illness invalidation. 
Significance of the Study 
Despite qualitative studies indicating that individuals with ME/CFS commonly 
experience illness invalidation (Asbring & Narvanen, 2002; Dickson, Knussen, & 
Flowers, 2007; Dickson, Knussen, & Flowers, 2008), the construct is relatively new to 
consideration in health psychology, and little quantitative research has been conducted 
in this area. Additionally, the majority of research on illness invalidation has been 
limited to studies of patients with rheumatic diseases (Kool, van Middendrop, Lumley, 
Bijlsma, & Geenen, 2012). Therefore, this study aimed to elucidate the impact of illness 
invalidation and social support upon shame experiences among ME/CFS sufferers. 
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Chapter Two 
Review of the Literature 
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 
Myalgic Encephalomyelitis has been classified in the World Health 
Organization’s International Classification of Diseases as a neurological disease 
(Carruthers & van de Sande, 2005). While fatigue is often highlighted in ME/CFS, it is 
only one of multiple symptoms within the disorder. Individuals with ME/CFS 
experience post-exertional malaise, slowed cognitive processing, hypersensitivity to 
sensory stimulation, sleep dysfunction, myalgia, and other symptoms (Carruthers et al., 
2003; Centers for Disease Control and Prevention, 1997; Fukuda et al., 1994; Furberg, 
Olarte, Afari, Goldberg, Buchwald, & Sullivan, 2005; Nisenbaum, Jones, Unger, Reyes, 
& Reeves, 2003).  
The term fatigue does not adequately describe the debilitating exhaustion, 
malaise, feelings of heaviness, and lightheadedness that individuals with ME/CFS 
experience (Carruthers & van de Sande, 2005). Markedly different from ordinary 
fatigue, in which loss of energy is easily restored by rest, individuals with ME/CFS 
typically experience at least a 50% reduction in activity levels as a result of 
incapacitating fatigue (Carruthers & van de Sande, 2005), and the severity of fatigue is 
experienced as “highly disproportionate to the activities preceding them” (de Carvalho 
et al., 2011, p. 5). Research comparing patients with ME/CFS to patients with multiple 
sclerosis (MS) found that individuals with ME/CFS scored higher on measures of 
fatigue than individuals with MS (Taillefer, Kirmayer, Robbins, & Lasry, 2002).  
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 Cognitive fatigue is often a component of ME/CFS, as well, with physical or 
cognitive demands resulting in slowed cognitive processing, decreased coherence, and 
struggles with retrieving information and/or words (Carruthers & van de Sande, 2005). 
This cognitive fatigue, often referred to as cognitive fog, is exhibited by impaired 
concentration, difficulties sustaining attention, forgetfulness, confusion, and slowed 
reaction time. Additionally, processing of complex information may be impaired. 
 In a meta-synthesis of 325 peer-reviewed qualitative studies of ME/CFS, the 
three symptoms most often reported by participants were severe fatigue, disabling pain, 
and cognitive difficulties (Anderson, Jason, Hlavaty, Porter, & Cudia, 2012). In 
contrast, a factor analysis of empirically-derived data from existing international 
datasets revealed that a five-factor model best explained ME/CFS (Hickie et al., 2009). 
The five domains were: (a) inflammation, (b) neurocognitive problems, (c) 
musculoskeletal pain and/or fatigue, (d) disturbed mood, and (e) disrupted sleep and/or 
fatigue. These factors were evident across cultures and throughout medical settings.  
Prevalence 
 Research by the U.S. Centers for Disease (CDC) found that prevalence of 
ME/CFS among adults over a four-year period varied from 3.8 to 5.2 cases per 100,000, 
based on geographical location (CDC, 1997). Data from the U.S. Mid-Atlantic Twin 
Registry (N = 4,591) found a 2.7% lifetime prevalence for ME/CFS symptoms (Furberg 
et al., 2005). A stratified community study in Chicago revealed a point-in-time 
prevalence rate of 2.2% (Jason et al., 1999), while a Wichita, Kansas study found a 
weighted point prevalence of 235 per 100,000 individuals (Reyes et al., 2003). Natural 
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history research found that rates of ME/CFS remained approximately unchanged over 
roughly ten years (Jason, Porter, Hunnell, Rademaker, & Richman, 2010). 
Diagnostic Challenges 
 One of the complexities of diagnosing ME/CFS lies in that distinctive laboratory 
tests are not yet available to identify the disorder, meaning that diagnosis is based upon 
symptoms, impaired functioning, and exclusion of other disorders that might explain 
symptoms (Reeves et al., 2003). Such exclusionary bases for diagnosis create 
difficulties in ascertaining the accuracy of diagnosis. 
The current quest for an ME/CFS biomarker centers upon inflammatory models 
of the disorder (Arnett & Clark, 2012). A distinct challenge, however, is that many of 
the biomarkers of inflammatory processes that appear to be involved in ME/CFS are 
also found in other inflammatory disorders, making reliance on inflammatory 
biomarkers for diagnosis problematic. However, recent research by Light and 
colleagues (2011) has identified changes in the expression of seven specific genes that 
differentiated a large subgroup of ME/CFS patients from healthy controls with accuracy 
of .80. It has been suggested that lab tests of these gene expressions could be combined 
with behavioral assessments to increase the accuracy of ME/CFS diagnosis.   
Diagnostic criteria: CFS Research Case Definition. The CFS Research Case 
Definition (Fukuda et al., 1994) is the most widely-utilized diagnostic criteria for 
ME/CFS (Brown et al., 2013). This diagnostic criteria requires a minimum of six 
consecutive months of sustained or recurrent fatigue that is of new onset, does not stem 
from exertion, is not resolved by rest, and leads to significant reductions in previous 
activities. In addition, at least four of the following symptoms must have occurred 
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concurrently throughout those six months: (a) diminished concentration or memory that 
impacts abilities to function in previous activities; (b) sore throat; (c) tender lymph 
nodes; (d) pain in muscles; (e) pain in multiple joints without redness or swelling; (f) 
headaches that differ in severity, pattern, or types from previous experience; (g) sleep 
that is not refreshing; and (h) malaise lasting for at least twenty-four hours following 
exertion. Furthermore, in order to arrive at diagnosis, clinicians must have completed: 
(a) a comprehensive medical and psychosocial history, (b) a mental status examination, 
(c) a complete physical examination, and (d) a battery of relevant laboratory screenings. 
When all other sources of symptoms are excluded, a diagnosis of CFS might be made.   
Illness Invalidation 
Illness invalidation has been defined as “a constellation of features that includes 
nonacceptance by others, misunderstanding, disbelief, rejection, stigmatization, and 
suspicion that the [health] problem is exaggerated or psychological” (Kool, 
Middendorp, Boeije, & Geenen, 2009, p. 1650). Illness invalidation may be particularly 
likely to occur when symptoms are invisible, ambiguous, and chronic.  
Individuals with chronic ambiguous conditions, including ME/CFS, have 
reported that their families and their medical professionals discounted their symptoms 
and doubted their experiences (Dickson et al., 2007; Johnson & Johnson, 2006). Illness 
invalidation has also been reported by patients with other “invisible” conditions, such as 
fibromyalgia (Kool et al., 2009), rheumatic diseases (Kool & Geenen, 2012) and 
chronic pain (Newton, Soutball, Raphael, Ashford, & LeMarchand, 2013). In qualitative 
research, individuals with ME/CFS have identified invalidation as “a defining response 
of others to their illness” and as a “pervasive and enduring experience” (Travers & 
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Lawler, 2008, p. 318). Moreover, patients with ME/CFS reported belief that absence of 
visibly-apparent symptoms contributed to illness invalidation (Asbring & Narvanen, 
2001; Dickson et al., 2007). 
Perspectives of medical professionals. As Clarke and James (2003) noted, 
“…one of the distinguishing features of ME/CFS is that its reality is disputed by the 
medical profession” (p. 1393). Research involving general practitioners from the United 
Kingdom revealed that 28% did not believe that ME/CFS was an identifiable clinical 
diagnosis (Bowen et al., 2005). In the United States, 20% of physicians indicated belief 
that ME/CFS is “only in the patient’s head” (Brimmer, Fridinger, Lin, & Reeves, 2010, 
p. 8). In a meta-synthesis of 325 peer-reviewed qualitative studies, physician-specific 
themes included skepticism that ME/CFS is a legitimate disorder and minimization of 
the ME/CFS illness experience (Anderson et al., 2012). Similarly, a meta-synthesis of 
studies spanning from 1988 to 2013 also echoed the finding that many medical 
professionals do not believe that ME/CFS is a real disorder, due to the limitations in 
pathological findings (Bayliss et al., 2014), current lack of objective tests to ascertain 
the disorder’s presence, and the lack of clearly-identified etiological mechanisms 
(Asbring & Narvanen, 2003). 
Medical doctors have been found to stereotype patients with ME/CFS, based on 
inadequate knowledge of the ME/CFS pathophysiology (Anderson et al., 2012). 
Physicians expressed perceptions of many ME/CFS patients as “illness focused, 
demanding, and medicalising” (Asbring & Narvanen, 2003, p. 711). In particular, 
physicians noted that individuals with ME/CFS do not act and appear the way someone 
who is ill “is expected to look and behave,” and they indicated that their assessment of 
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physical appearance weighed heavily in their interpretation of the legitimacy of a 
patient’s symptom description (Asbring & Narvanen, 2003, p. 714). Medical doctors 
made judgments about the veracity of their ME/CFS patients’ reports and often 
questioned the morality of the patient, especially of the individual’s work ethic. 
Similarly, Swedish physicians who treated ME/CFS patients also revealed skepticism 
about patient experiences, noting belief that the symptoms of ME/CFS were minor, that 
patients were exaggerating the severity of their illness experiences, and that these 
patients had particularly pessimistic attitudes about life (Asbring & Narvanen, 2003).  
Factors significantly associated with medical professionals endorsing the 
legitimacy of ME/CFS were: (a) having a personal acquaintance with ME/CFS, (b) 
being male, and (c) having treated a greater number of ME/CFS patients within the 
previous year (Bowen et al., 2005). Physicians who had previously given an ME/CFS 
diagnosis were less likely to believe that the disorder was “in a patient’s head” 
(Brimmer et al., 2010, p. 8).  
Perspectives of patients. Patients with ME/CFS have reported having their 
symptoms met with skepticism, disbelief, trivialization, and dismissal by medical 
professionals (Cooper, 1997; Deale & Wessely, 2001; Gilje, Soderlund, & Malterud, 
2008). ME/CFS patients have described finding their interactions with doctors to be 
more frustrating than helpful (Clarke, 1999) and perceiving that healthcare 
professionals did not listen to them (de Carvalho et al., 2011). Individuals with ME/CFS 
reported experiencing their physicians as doubting the legitimacy of their illness, 
disbelieving that the symptoms stemmed from organic causes (Clarke & James, 2003), 
and generally misunderstanding the nature of their sickness (Cooper, 1997; de Carvalho 
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et al., 2011). In one study, over half of participants with ME/CFS (N = 211) reported 
belief that medical specialists did not seriously consider their complaints (53%) and did 
not sympathize with their illness experiences (54%; Prins et al., 2000). Further, 
ME/CFS patients have reported “being treated with disdain” and as “an annoying 
irritation” by their physicians (Arroll & Senior, 2008, pp. 453-454).  
In other research, patients indicated that the impact of ME/CFS symptoms was 
significant, and yet, review of their medical records found that symptoms of fatigue 
were rarely included in medical documentation (Evengard et al., 2005). These results 
provide convergent support for the discrepant perspectives of symptoms by patients and 
their physicians.  
Impact of illness invalidation from medical professionals. In Western culture, 
medical professionals are culturally-sanctioned as having power to officially recognize 
an individual’s symptoms as medically- and socially-legitimate (Cooper, 1997; 
Foucault, 1975; Hyden & Sachs, 1998; Woodward, Broom, & Legge, 1995). Foucault 
(1975) considered this power to be a form of medical policing, and others have 
interpreted it as “medical paternalism” (Finerman & Bennett, 1995, p. 2; Kirmayer, 
1988). Within such a culture, some patients are not granted a medical sanction for their 
illness, particularly those individuals whose symptoms are difficult to diagnose or who 
suffer from ambiguous or chronic health conditions (Chrisman, 1977; Waxler, 1980). 
Without this medical sanction, illness invalidation from medical professionals may have 
a pronounced negative impact on patients.  
Having medical professionals fail to validate symptoms has reportedly 
contributed to individuals with medically unexplained illnesses questioning themselves, 
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even when they knew their symptoms to be real (Nettleton, 2006). Patients with 
ME/CFS have reported feeling confused, disempowered, self-doubting, and vulnerable, 
as well as experiencing loss of identity, upon perceiving illness invalidation from 
medical professionals (Arroll & Senior, 2008; Woodward et al., 1995). Patients have 
also reported perceiving the lack of positive support from their doctors as leading to 
“deterioration in emotional well-being” (de Carvalho et al., 2011, p. 7). This type of 
interaction has been referred to as “psychogenic dismissal,” a term used to describe an 
experience wherein a patient experiences iatrogenic psychological harm as a result of 
having their symptoms dismissed as being “all in the mind” (p. 202). Thus, it comes as 
no surprise that in a systematic literature review, a major area of expressed need for 
patient with ME/CFS was to receive empathy and respect from healthcare providers (de 
Lourdes Drachler, 2009). 
In addition, patients indicated that, in their struggle to obtain a legitimate 
diagnosis, they often felt a great deal of pressure to demonstrate that they were 
genuinely ill and to appear to be “good” or “normal” patients (Cooper, 1997, p. 199). 
They noted experiencing the need to prove that, although their illness might be 
considered “deviant,” they were not deviant themselves (p. 199). On the other hand, 
patients have reported withholding information about their symptoms, when interacting 
with medical professionals who were perceived as invalidating (Nettelton, 2006).  
Individuals with ME/CFS noted that illness invalidation from medical 
professionals often contributed to invalidation from family, employers, and social 
networks and to decreased social support (Cooper, 1997; de Carvalho et al., 2011). As 
one patient described it: 
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I was more or less bed bound for a couple of years, …and meanwhile the 
doctors were telling me there was nothing wrong with me. So I was under 
pressure from employers, family and everyone else to stop imagining that I was 
ill, and to get out of bed and get on with my life. (de Carvalho et al., 2011) 
Illness invalidation from social networks. Despite having a diagnostic label to 
explain their symptoms, ME/CFS patients reported that the lack of visible symptoms 
contributed to illness invalidation from social networks (Fisher & Crawley, 2012). 
Patients reported having their symptoms trivialized and having others explain to them 
that “tiredness” is a normal experience (p. 564). Patients often reported that friends 
were skeptical of the legitimacy of their sickness, that they were judged and rejected by 
many in their previous social networks, and that they often lost their friendship 
networks (Clarke & James, 2003).  
Adolescent patients reported that some friends and teachers invalidated their 
experiences of fatigue, doubting them, appearing to distrust their reported symptoms, 
dismissing their illness as malingering, and attributing their physical inabilities to 
laziness (Fisher & Crawley, 2012). Further, adolescents with ME/CFS noted having 
difficult experiences of teasing and bullying about their illness from peers.  
Moreover, individuals with ME/CFS reported experiencing emotional pain as a 
result of illness invalidation from significant others, family members, friends, and the 
work environment (Asbring & Narvanen, 2002; Dickson et al., 2007; Larun & 
Malterud, 2007). The experiences of both illness invalidation and physical limitations 
often led individuals to believe that they were no longer entitled to their former 
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relationships, that they were now inferior in their interpersonal worth, and to a general 
sense of painful relational disconnection (Travers & Lawler, 2008). 
In a meta-synthesis of 325 peer-reviewed qualitative studies of ME/CFS, a 
common theme among patients was the experience of reduced social connections and 
disrupted personal relationships in association with the illness (Anderson et al., 2012). 
ME/CFS patients often reported feeling socially isolated and as though they were 
“outsiders” (Clark & James, 2003, p. 1390). Biro (2012) described this process as 
follows:  
…[The ill] suffer just as much, if not more, because they feel isolated from 
others, because they feel alone. So the circle widens once again: the body 
unravels, the self unravels, and now our relationship with the world unravels. (p. 
47)  
Illness invalidation from family. In qualitative research, patients reported that 
few of their family members continued to support them and to validate their illness 
(Clarke & James, 2003). Invalidation of illness experiences by a spouse were 
considered particularly emotionally difficult (Dickson et al., 2007) and were negatively 
related to adaptive outcomes (Heijmans, DeRidder, & Bensing, 1999). As one patient 
described it, 
The difference with friends – if they’re not helpful you don’t have to talk to 
them, but with [family] you have to – you can’t choose your family. So you 
learn what to say and what not to say. (Clarke & James, 2003, p. 1391).  
 
 
13 
 
Shame 
Shame has been defined as an individual’s global assessment of the self as 
inferior, deficient, and of diminished value (Woien, Ernst, Patock-Peckham, & Nagoshi, 
2003). In qualitative research, adults have described shame as eroding positive self-
concept, harming one’s sense of connection with others, and ultimately, bringing about 
perceived loss of power (Van Vliet, 2008). Shame has been conceptualized as an 
emotional response that originates from interpersonal transactions (Tangney, Miller, 
Flicker, & Hill Barlow, 1996), evaluative social conditions, and threats to the social self 
(Dickerson, Gruenwald, & Kenemy, 2004; Dickerson, Gruenwald, & Kemeny, 2009). 
Shame is particularly likely to be evoked in situations in which a component of one’s 
identity is, or has the potential to be, negatively evaluated by others (Dickerson et al., 
2004).  
While shame is considered a negative evaluation of oneself, it is believed to be 
linked to the social environment, to the belief that a critical “imagined other” is judging 
the self (Lewis, 1971), and to cultural expectations (Martens, 2005). Shame has also 
been posited as resulting from discrepancies between external expectations and 
assessment of internal realities, and as “an emotion which has incorporated the gaze and 
the voice of the other” (p. 404). Scheff (2000) described shame as a “social emotion” 
that arises from “threat to the social bond” (p. 97). Also, Dickerson and colleagues 
(2004) described shame as resulting “when perceptions of negative social evaluation are 
transformed into negative self-evaluation” (p. 1195).  
Shame has also been conceptualized as an emotional response to low social 
standing and the associated risks of interpersonal rejection, exclusion, or maltreatment 
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(Balsamo et al., 2014; Dickerson et al., 2004). Research found that, among psychology 
students, a strong positive correlation existed between blaming oneself for having been 
socially criticized or “put-down” and the experience of shame (Gilbert & Miles, 2000, 
p. 768). Indeed, social rank and experiences of shame have been found to be highly 
correlated (Cheung, Gilbert, & Irons, 2004; Gilbert, 2000). The social aspect of shame 
has been reflected in qualitative research, as well. In a study consisting of nearly one 
hundred autobiographical narratives, results revealed that, in situations in which 
participants wrote shameful statements, the participants’ writing focused upon how 
others might be negatively evaluating them (Silfver, 2007). 
Illness and Shame. Anthropologists have noted that Western culture has shifted 
toward new explanatory models of illness that are “blame focused” and that place 
responsibility for disease processes and their outcomes upon the patients themselves, 
often ignoring the complexities of disease processes (Finerman & Bennett, 1995, p.1). 
These attributions of patient responsibilities for their illnesses may stem from increased 
lay and professional education about connections between lifestyle choices and disease. 
Such attributions ignore the reality that health difficulties are often induced by multiple 
causes and are frequently complex. However, the emphasis on patient accountability for 
lifestyle choices may translate into interpretations of sick individuals as blameworthy 
for their illnesses. 
An example of this phenomenon of focusing blame on patients for their illness, 
while ignoring complexities of diseases processes, is reflected in results from qualitative 
research in the United Kingdom. Research there found that individuals with lung cancer 
who had no prior history of smoking considered themselves as being unfairly blamed by 
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those around them for their disease (Chapple, Ziebland, & McPherson, 2004). 
Furthermore, some patients noted belief that media reports linking smoking to lung 
cancer may have contributed to the assessment that they were to blame for their cancer. 
Qualitative research involving patients visiting a Danish general practice revealed that 
patients who were not successfully managing their health acknowledged that they were 
failing to fulfill others’ expectations and experienced shame (Guassora, Reventlow, & 
Malterud, 2014). Similarly, patients with obesity reported feeling shame in relation to 
messages of blame from the dominant culture (Kirk et al., 2014).  
Multiple studies point to individuals with health difficulties experiencing shame 
pertaining to their physical condition and subsequently choosing to isolate from social 
circles. For example, patients with chronic back pain reported feelings of shame 
associated with relational contexts in which they perceived critical judgments from 
others (Smith & Osborn, 2007). These patients reported engaging in social withdrawal 
and avoidance in association with shame. Similarly, patients with irritable bowel 
syndrome (IBS) reported experiencing shame associated with intimate relationships, 
resulting in avoidance of situations where they might be socially embarrassed 
(Hakanson, Sahlberg-Blom, Nyhlin, & Ternestedt, 2009). Norwegian women who had 
weight-loss surgery and who experienced difficulties with chronic pain and fatigue 
afterward, or who began to regain the lost weight, were found to experience shame 
regarding others’ perceptions of their choices and to restrict their social interactions 
(Groven, Raheim, & Engelsrud, 2010). Individuals with ME/CFS have reported shame 
in connection with failures to conform to social expectations, including the cultural 
norm that illnesses be physiologically observable, and in connection with experiences of 
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illness invalidation (Travers & Lawler, 2008). These experiences of shame were 
associated with social isolation and disconnection.  
Shame has also been found to negatively correlate with psychological wellbeing, 
and this finding has been found to sustain across the lifespan (Orth, Robins, & Soto, 
2010). Individuals living in Greece who were ashamed of past experiences of physical 
pain were found to have higher levels of psychopathology than individuals who had not 
experienced shame surrounding physical pain (Paschou, Damigos, Mavreas, & Gouva, 
2010). Additionally, external shame (shame stemming from negative evaluations by 
others) has been found to correlate with experiences of depression and with submissive 
behaviors (Cheung et al., 2004; Kim, Thibodeau, & Jorgensen, 2011).  
Research indicates that social-evaluative threat and shame may have negative 
effects on physical health, as well. Experiences of shame have been found to have a 
positive relationship with proinflammatory cytokine activity, suggesting that shame 
may result in immunological changes (Dickerson, Kemeny, Aziz, Kim, & Fahey, 2004). 
Additionally, a meta-analysis of 208 research studies found that stress stemming from 
uncontrollable social-evaluative threats was associated with significant increases in 
cortisol and adrenocorticotropic hormone (Dickerson & Kemeny, 2004). Further, in 
research conducted in Norway, higher reports of shame were associated with increased 
likelihood of protracted illness-related absences the following year (Knapstad, 
Overland, Henderson, Homgren, & Hensing, 2014). And, experiencing shame in 
association with medical care has been linked to avoidance of healthcare utilization or 
lying to doctors, in order to avoid repeated experiences of shame (Green et al., 2010).   
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Illness Invalidation and Shame 
Discussing one’s illness within the context of an invalidating environment may 
lead to internalized shame (Myers, 2004). Ware (1992) proposed that, when the 
subjective experience of one’s illness is denied by the social context, shame of “being 
wrong in one’s definition of reality” may occur (p. 347). Indeed, women with ME/CFS 
reported experiencing discrepancies between their own definition of their experience 
and the perceptions of their work environment and their physicians (Asbring & 
Narvanen, 2001).  
Individuals with ME/CFS have expressed feelings of shame associated with 
illness invalidation and of experiencing their identity as questioned and no longer 
legitimate (Larun & Malterud, 2007). In qualitative research, participants sometimes 
attributed their experience of shame to physicians, members of the media, and other 
individuals having expressed the belief that ME/CFS was “all in their heads” (Clarke & 
James, 2003, p. 1390). Some individuals with ME/CFS even reported removing 
themselves from their former social lives out of feelings of shame over how others 
perceived them or after having others reject that their illness was legitimate (Clarke & 
James, 2003).  
In research involving a large sample of adults (N = 915), half of the participants 
reported experiencing at least one interaction with a medical doctor in which they felt 
ashamed, with shame-provoking situations including those in which a physician 
engaged in illness invalidation of their health complaints (Harris & Darby, 2009). 
Similarly, a majority of Swedish patients who had experienced negative encounters 
within healthcare settings, including having their provider not believe them, doubt their 
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condition, or question their motivation to work, identified feelings of shame (Lynoe et 
al., 2013). 
Social Support and the Stress Buffering Model 
The Stress Buffering Model proposes that social support mitigates the negative 
effects of stress and promotes wellbeing (Cohen & Wills, 1985). Social support is 
conceptualized as manifesting across four support domains. Esteem support refers to 
communication that the individual is valued, worthy, and accepted. Informational 
support is operationalized as provision of coping support, advice, and guidance. Social 
companionship refers to time spent with others that is accompanied by a sense of 
belonging. Finally, instrumental support refers to assistance with tangible needs.   
According to the Stress Buffering Model, esteem support counteracts threats to 
self-concept that may occur during stressful periods by communicating valuing and 
acceptance (Cohen & Wills, 1985). Informational support may promote cognitive 
reappraisals of stressful situations and/or may contribute to successful coping strategies. 
On the other hand, instrumental support and social companionship meet practical and 
affiliation needs during taxing times.  
Existing research appears to support the Stress Buffering Model, with evidence 
of the emotional benefits of social support to patients with health concerns indicated 
across multiple studies. Among individuals with rheumatic diseases, social support has 
been found to significantly relate to improved mental health (Kool et al., 2012). 
Specifically, individuals with rheumatoid arthritis who received higher amounts of daily 
emotional support were more likely to report increased psychological wellbeing, 
decreased anxiety, fewer sleep difficulties, and less depression (Demange et al., 2004). 
19 
 
Similarly, research involving individuals with advanced cancer in Spain, revealed a 
significant moderate positive correlation between perceived social support and having a 
positive focus (Zabalegui, Cabrera, Navarro, & Cebria, 2011). Among survivors of 
hematopoietic stem cell transplant, emotional and instrumental social support predicted 
posttraumatic growth (Nenova, DuHamel, Zemon, Rini, & Redd, 2013). Furthermore, 
in a study of patients with HIV in Nepal, global satisfaction with social support 
significantly predicted quality of life, with the mediating effect of social support being 
hope (Yadav, 2010).  
Social support has also been linked to health-related quality of life, as well. A 
literature review of 175 studies of social support and coping among prostate cancer 
patients revealed that the preponderance of research has indicated that perception of 
social support exerts a main effect upon health-related quality of life (Paterson, Jones, 
Rattray, & Lauder, 2013). Social support has also been linked to health-related quality 
of life in patients with heart failure (Bakan & Akyol, 2008). In addition, global 
satisfaction with social support predicted health-related quality of life among heart 
transplant recipients at five years post-transplant, and satisfaction with emotional 
aspects of social support predicted health-related quality of life at ten years post heart 
transplant (White-Williams et al., 2013). Among patients with diabetes in Turkey, 
perceived social support was positively correlated with quality of life as well (Goz, 
Karaoz, Goz, Ekiz, & Cetin, 2007).  
In regard to the moderating effects of social support on health specifically, 
however, the Stress Buffering Model was not supported in a sample of Dutch and 
Belgian individuals with rheumatic diseases (Kool, Middendorp, Lumley, Bijlsma, & 
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Geenen, 2012). Thus, it may be that the buffering effects of social support are more 
likely to be found with regard to emotional wellbeing than actual physical health. 
Individuals who lack medical explanations of illness symptoms have reported 
experiencing isolation and lack of social support (Nettleton, 2006). Patients with 
ME/CFS have expressed feelings of loneliness and separation from others, following 
perceived rejection by friends and significant others (Dickson et al., 2007), and 
adolescents with ME/CFS have noted perceiving that their inability to engage in 
activities as before had tested their relationships (Fisher & Crawley, 2012).  
Many patients with ME/CFS noted belief that receiving social support and 
validation would have increased their quality of life and facilitated coping (Dickson et 
al., 2007). Additionally, individuals with moderate to severe ME/CFS indicated that 
social support was particularly important to them in practical areas of personal care, 
assistance with family responsibilities, and help with domestic chores (de Carvalho et 
al., 2011). In a systematic literature review, among the needs expressed by patients with 
ME/CFS was a strong desire for positive support from social networks (de Lourdes 
Drachler et al., 2009).  
Research results have indicated that when members of patients’ social networks 
understood that ME/CFS was seriously impacting their functional abilities, trust was 
increased in those relationships (Fisher & Crawley, 2012). Additionally, patients with 
ME/CFS who experienced continued social support, following illness onset, reported 
deeply valuing those relationships (Clark & James, 2003).  
 However, research on the ameliorative impact of social support among 
individuals with ME/CFS has been limited, further justifying the current study. 
21 
 
Illness Invalidation, Shame, and the Stress Buffering Model 
Discussing one’s illness within the context of an invalidating environment may 
lead to internalized shame (Myers, 2004). Indeed, individuals with ME/CFS have 
expressed feelings of shame associated with the invalidation of their symptoms and 
having their experiences discounted, minimized, or dismissed (Larun & Malterud, 
2007).  
According to the Stress Buffering Model, esteem support from social connection 
may help counteract threats to self-concept that may occur during stressful periods by 
communicating valuing and acceptance (Cohen & Wills, 1985). In fact, adults who 
considered themselves to have recovered from shame identified the following as helpful 
to their achieving healing from shame: (a) finding at least one or two individuals who 
supported them and offered unconditional acceptance, (b) connecting socially with 
others, (c) communicating with at least one person about their shame event and 
experiencing that person as listening, understanding, and maintaining belief in their 
positive attributes (Van Vliet, 2008).   
Hypotheses 
Although qualitative studies have indicated that individuals with ME/CFS 
commonly experience illness invalidation (Asbring & Narvanen, 2002; Dickson, 
Knussen, & Flowers, 2007; Dickson, Knussen, & Flowers, 2008), the construct is 
relatively new to consideration in health psychology, and little quantitative research has 
been conducted in this area. To date, no peer-reviewed quantitative studies have been 
published that evaluate experiences of illness invalidation in the ME/CFS population. 
22 
 
Therefore, this study aimed to elucidate the impact of illness invalidation and social 
support upon shame experiences among ME/CFS sufferers. 
Based upon existing qualitative research, indicating connections between illness 
invalidation and shame (e.g., Asbring & Narvanen, 2002; Dickson, Knussen, & 
Flowers, 2007; Dickson, Knussen, & Flowers, 2008), it was hypothesized that there 
would be a positive and significant relationship between illness invalidation and state 
shame. From the theoretical foundation of the Stress Buffering Hypothesis (Cohen & 
Wills, 1985), it was further hypothesized that social support would moderate the 
relationship between illness invalidation and shame, with the relationship between 
illness invalidation and state shame changing significantly based on level of social 
support. 
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Chapter Three 
Methods 
Participants 
Individuals were recruited to participate if they were between the ages of 18-64, 
identified as being ill with ME/CFS, and were not pregnant. Participants were recruited 
via ME/CFS and chronic illness support web sites, web sites for ME/CFS advocacy and 
research, and social networking sites. A snowball recruitment method was utilized, with 
participants encouraged to forward the survey to other potential participants.  
One hundred eighty-five participants responded to the survey. Of those, ten 
recruits declined participation, three participants denied having ME/CFS, and four 
individuals agreed to participate, but subsequently, chose not to complete the survey. 
Thus, the final N = 168.  
As indicated in Table 1 (Appendix A), the mean age of participants was 45.5 
years (n = 137, SD = 11.12, range 18-64), with 8.5% between the ages of 18-30, 13.4% 
between the ages of 31-40, 26% between the ages of 41-50, 20.5% between the ages of 
51-60, and 5.4% between the ages of 61-64. A relatively large percentage (25.9%, n = 
48) of participants elected not to reveal their age. The self-identified gender of 
participants was 68.1% female, 6.5% male, and 0.5% other, with a number of 
participants (24.9%, n = 46) opting not to reveal their gender (see Appendix A, Table 
1).  
Participants identified their racial/ethnic background as 64.9% Caucasian, 0.5% 
Native American/American Indian, 0.5% African origin, 0.5% Asian origin, and 8.1% 
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Other (refer to Appendix A, Table 1). Approximately one-fourth (25.4%, n = 47) of 
participants did not identify their racial/ethnic background. 
In regard to marital status, 37.3% identified as married, 18.4% as single, 11.4 % 
as divorced, 0.5% as widowed, and 7.6% as other (see Appendix A, Table 1). Roughly 
one-fourth of participants (24.9%) opted not to answer questions regarding marital 
status. 
Nearly half of participants reported having completed a college degree (45.4%), 
with 7.6% having an associate’s degree, 18.9% reporting a bachelor’s or equivalent 
professional degree, 16.2% indicating a master’s or equivalent professional degree, and 
2.7% reporting a doctorate or equivalent professional degree. Of those who had not 
completed a college degree, 14.1% had completed some college, 7.6% had completed 
vocational training, 10.3% had completed high school, 1.6% had completed junior 
high/middle school, and 3.2% indicated their education as Other (refer to Appendix A, 
Table 1).  
Despite being a relatively well-educated sample, 43.7% of participants indicated 
household incomes of $29,000 per year or less. Roughly half of participants (47.6%) 
reported being without employment, and 45.9% indicated disability status.  
Regarding length of time since onset of ME/CFS symptoms, 2.7% of 
participants had experienced symptoms for less than one year, 10.8% for one to three 
years, 12.4% for four to six years, 15.1% for seven to 10 years, 18.9% for 11-20 years, 
8.6% for 21-30 years, and 4.3% for over 30 years. Twenty-seven percent (27%) of 
participants did not answer questions regarding duration of symptoms. There was wide 
variability in length of time between symptom onset and diagnosis with ME/CFS, with 
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9.7 % being diagnosed within six months or less of symptom onset, 15.7% within six 
months to one year, 23.2% between two and four years, 8.1% within five to seven years, 
7.6% between eight and 10 years, and 9.2% in 11 or more years. A large number of 
participants (n = 49; 26.5%), however, chose not to respond to this item.  
Participants described their current symptom status as follows: intense 
symptoms and/or many problematic symptoms (39.5%), moderate symptoms (22.2%), 
mild symptoms (5.9%), and symptoms in remission (0.8%). As with previous 
demographic items, a large number of participants (n = 59; 31.9%) chose not to 
designate their current symptom status.  
Participants were asked to rate, on a scale of 0-100, the severity of their 
ME/CFS symptoms, with “0” indicating total absence of symptoms and increasingly 
higher numbers indicating increased severity of symptoms. Participants provided ratings 
ranging from 28-100. The mean rating for ME/CFS symptom severity was 69.93 (SD = 
15.57), with 3.7% of responding participants reporting severity between 28-40, 13.4% 
indicating limitation ratings of 41-60, 33.0% between 61-80, and 15.4% between 81-
100. The percentage of participants who chose not to rate their symptom severity was 
34.1% (n = 63). 
Additionally, participants were asked to rate, on a scale of 0-100, how limited 
they were by their ME/CFS symptoms, with “0” indicating total absence of limitations 
and increasingly higher numbers indicating increased limitations by symptoms. 
Participants provided ratings ranging from 20-100. The mean rating for limitations was 
70.36 (SD = 17.35), with 5.8% of participants rating their limitations between 20-40, 
13.9% indicating limitations of 41-60, 25.6% between 61-80, and 22.6% between 81-
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100. Finally, 31.4% (n = 58) elected not to rate their limitations from ME/CFS 
symptoms.  
Roughly thirty five percent (35.1%) of participants reported being involved in a 
support group for individuals with ME/CFS.  
Instruments 
Demographic questionnaire. A demographic questionnaire was created by the 
author for use in this study (Appendix C). Demographic information was requested 
regarding gender, racial/ethnic background, highest level of education attained, 
employment, disability status, and income. Participants were also asked questions 
pertaining to time since ME/CFS symptom onset, time from symptom onset to 
diagnosis, symptom severity, and symptom-related limitations.   
Illness Invalidation Inventory. The Illness Invalidation Inventory (I*3; Kool et 
al., 2010) is a 40-item self-report measure that assesses perceived illness invalidation 
from five sources: spouse, family, medical professionals, work environment, and social 
services (Appendix C). In factor analysis conducted by the measure’s authors, I*3 
statements were found to load on two factors of invalidation: Discounting and Lack of 
Understanding. Thus, the I*3 was divided into two subscales, Discounting and Lack of 
Understanding.  
Each subscale of the I*3 contains eight statements, rated on a 5-point Likert 
scale (ranging from “never” to “very often”; Kool et al., 2010). A sample “Discounting” 
item is “ My….finds it odd that I can do much more on some days than on other days.” 
An example of a “Lack of Understanding” item is “My….takes me seriously” (R). A 
source subscale that does not apply (e.g., because the participant was not married or was 
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unemployed) is automatically skipped. Twenty-four items are reverse scored. Subscale 
scores are obtained by averaging scores for all items in the respective subscales.  
In the current study, Cronbach’s alpha for the overall I*3 measure was good, 
with (.91). Likewise, Cronbach’s alphas were also good for the subscales, Lack of 
Understanding (.88) and Discounting (.85). (All reliability results may be found in 
Appendix A, Table 2.)   
The State Shame and Guilt Scale. Measures of shame fall into two categories: 
(1) those that assess trait shame, and (2) those that measure state shame (Robins, 
Noftle, & Tracy, 2007). Measures of trait shame assess one’s shame-proneness as an 
enduring aspect of the personality. Measures of state shame, on the other hand, assess 
whether one experiences shame at a certain point in time, and such instruments may be 
used to measure shame in response to situational factors. For the purposes of this study, 
it was preferable that shame be measured in regard to one’s experiences of perceived 
illness invalidation, rather than in regard to one’s personality. As a result, the State 
Shame and Guilt Scale (SSGS; Marschall, Sanftner, & Tangney, 1994), a measure of 
state shame, was selected (Appendix C). 
The State Shame and Guilt Scale (Marschall et al., 1994) is a 15-item (five items 
in each of three subscales) self-report instrument developed to measure Shame (the self 
as intrinsically bad), Guilt (the self as having behaved poorly), and Pride (the self as 
valued; Marschall et al., 1994). Subscale items were reportedly developed in light of 
empirical and theoretical literature (Dearing & Tangney, 2002). Sample items include, 
“I feel worthwhile, valuable;” “I feel small;” and, “I feel worthless, powerless” 
(Marschall et al., 1994).  
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Participants indicate their agreement/disagreement with statements on a five-
point Likert scale. All items are scored in a positive direction. Only the Shame subscale 
was utilized in data analysis, as it was the only SSGS subscale pertinent to the study’s 
hypothesis. Shame subscale scores were calculated by obtaining mean scores. In the 
current study, Cronbach’s alpha for the State Shame subscale was .80 (refer to 
Appendix A, Table 2). 
 The Medical Outcomes Study Social Support Survey. The Medical Outcomes 
Study Social Support Survey (MOS; Sherbourne & Stewart, 1991) is a 19-item self-
report measure of social support that was designed specifically for use with patients 
with chronic illness (Appendix C). The MOS includes four subscales that measure 
various dimensions of social support, namely emotional/informational, tangible, 
affectionate, and positive social interaction.  
 The MOS (Sherbourne & Stewart, 1991) was developed in light of the Stress 
Buffering Hypothesis (Cohen & Wills, 1985) and current theory regarding social 
support outlined in the existing literature. In order to minimize participant fatigue, 
social support was measured without respect for the source (e.g., whether social support 
came from friends, community, religious circles, etc.). Items were found to discriminate 
from measures of loneliness, mental health, feelings of belonging, perceptions of 
current health, and other dimensions of family and interpersonal functioning. In the 
measure’s development, internal-consistency reliability was found to be high for each 
subscale, with alphas ranging from .91 to .97, and one-year stability coefficients ranged 
from .72 to .78. In the current study, Cronbach’s alpha = .96 for the overall scale (see 
Appendix A, Table 2). 
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 The MOS Emotional/Informational Support subscale consists of eight items that 
assess participant experiences of having someone in their life who expresses positive 
feelings, empathy, understanding, and encouragement of expression of emotion, as well 
as someone who offers suggestions, guidance, information, or feedback. The Tangible 
Support subscale is comprised of four items that evaluate experiences of receiving 
material or physical assistance from others. The Positive Social Interactions subscale is 
composed of three items that evaluate the experience of relationships that include 
enjoyable experiences and activities to the participant. The Affectionate Support 
subscale contains three items that assess whether the participant has someone in their 
life who expresses positive regard, fondness, and love toward them. For each item, 
participants rate the availability of that particular support on a 5-point Likert scale, 
ranging from “None of the Time” to “All of the Time.” Example items include: 
“Someone to confide in or talk to about yourself or your problems…;” “Someone to 
share your most private worries and fears…;” and, “Someone who understands your 
problems….”  
 All MOS items are scored in a positive direction (Sherbourne & Stewart, 1991). 
Subscale scores are calculated by averaging all scores on each respective subscale, and 
the Overall Support Index score is obtained by averaging the mean of all subscale 
scores and the additional item score (Rand Corporation, n.d.).  
 Results of principle components factor analysis supported the use of an overall 
total score (Overall Support Index; Sherbourne & Stewart, 1991). Multitrait and 
confirmatory factor analyses supported the use of MOS subscale scores, as well. 
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Further, the authors recommended the option of utilizing subscale scores in research, 
based upon their usefulness in testing theoretical hypotheses.  
Procedure 
The University of Oklahoma Institutional Review Board reviewed and approved 
this study (Appendix B). An online survey was created via Qualtrics, and was 
maintained via a secure server in the University of Oklahoma’s Center for Educational 
Development and Research. Links to the study were posted on ME/CFS and chronic 
illness support web sites, web sites of ME/CFS advocacy and research organizations, 
and social networking sites. Participation was voluntary, without remuneration. 
Informed consent to participate was obtained electronically by providing an information 
sheet regarding the study and with participants clicking on whether they agreed to 
participate or not. If participants indicated that they did not wish to participate, they 
were immediately exited from the survey. Following consent, participants could skip 
questions or exit the survey at any time. No identifying information was collected. 
Following informed consent, instruments were administered in the following 
order: I*3, MOS, SSGS, and Demographic Questionnaire.  
Data Analysis 
It was predicted that participants with ME/CFS would exhibit a significant 
positive relationship between their report of perceived illness invalidation and 
experiences of shame. Further, it was predicted that those who received more social 
support would evidence a significantly weaker positive relationship between illness 
invalidation and shame, due to the buffering effects of social support.  
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Preliminary analysis included assessment for violations of parametric 
assumptions, including review of the P-P plot and evaluation of skewness and kurtosis 
in the data. Additionally, Kolmogorov-Smirnov and the Shapiro-Wilk tests were 
utilized to assess for normality. After removing one item that contained an extreme 
outlier from the data set, no violations of normality were observed. 
A hierarchical multiple regression was utilized to test the hypothesis that the 
MOS Overall Support Index would moderate the relationship between I*3 Lack of 
Understanding and SSGS Shame. Moderator variables are intended to affect the 
direction and/or strength of the relationship between a predictor variable and the 
outcome variable (Baron & Kenny, 1986), and hierarchical multiple regression is 
considered the preferred method for identifying the presence or absence of moderating 
effects when the predictor and/or moderator variables are measured on a continuous 
scale (Aiken & West, 1991). It is important to note that, in hierarchical regression, 
moderators may, or may not, be significantly related to the predictor or the outcome 
variable, and the predictor may or may not be correlated to the outcome (Frazier et al., 
2004).  
Some have argued that centering of predictor variables is no longer considered a 
necessary step in hierarchical regressions, as centering has reportedly been found to 
change the intercept, without affecting the shape of the moderation results (Jose, 2013). 
However, as a precaution, variables were centered in the current study.  
Since correlation analyses revealed significant relationships between select 
demographic variables (i.e., income and length of time since symptom onset) and the 
outcome variable (i.e., SSGS Shame), these demographic variables were entered into 
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the first step of the regression model, in order to control for their effects on SSGS 
Shame. Subsequently, I*3 Lack of Understanding was entered into the second step, and 
the MOS Overall Support Index was entered into the third step. Finally, the interaction 
between I*3 Lack of Understanding and the MOS Overall Support Index was entered 
into the fourth step. 
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Chapter Four 
Results 
Preliminary Analyses 
 Preliminary examination of the data revealed one extreme outlier. After 
removal, no violation of the assumptions of normality, linearity, multicollinearity, and 
homoscedasticity were observed.   
 Means and standard deviations of the predictor and criterion variables included 
in the overall model are given in Table 2 (Appendix A). Pearsons’s bivariate 
correlational analyses of relationships between the variables of interest are summarized 
in Table 3 (Appendix A).  
Demographic variables that significantly correlated with SSGS Shame included 
income, marital status, and length of time since symptom onset. Annual income of 
participants evidenced a significant negative relationship with SSGS Shame (r = -.19, p 
 .05), indicating a trend toward individuals with lower income reporting higher levels 
of state shame. Length of time since symptom onset was also significantly and 
negatively related to SSGS shame (r = -.20, p  .05), such that those who were newer to 
the symptom experience were more likely to experience shame.  
Race evidenced a significant negative relationship with the Lack of 
Understanding subscale of the I*3 (r = -.24, p  .01), such that participants of color 
reported higher levels of illness invalidation in the form of Lack of Understanding. 
Further, participant ratings of the severity of their ME/CFS symptoms were 
significantly positively related to their experiences of illness invalidation in the form of 
discounting (I*3 Discounting), r = .15, p < .05, indicating that participants who reported 
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greater symptom severity also experienced greater levels of illness invalidation in the 
form of discounting. 
Income also evidenced significant relationships with the MOS Overall Support 
and with all of the four MOS subscales. MOS Overall Support was significantly 
positively correlated with income (r = .26, p  .01), such that increases in income 
corresponded to increases in overall social support. Positive Social Interactions subscale 
scores were also significantly positively correlated with income (r = .33, p  .01), as 
were Affectionate Social Support (r = .27, p  .01), Emotional/Informational Support (r 
= .21, p  .05), and Tangible Social Support (r = .17, p  .05). 
In regard to the variables of interest, illness invalidation in the form of lack of 
understanding (I*3 Lack of Understanding) was significantly correlated with state 
shame (SSGS Shame), r = .15, p < .05. However, illness invalidation in the form of 
discounting (I*3 Discounting) was not significantly related to shame (SSGS Shame), r = 
.11, p = .10.  
Overall perceived social support (MOS Overall Support Index) evidenced a 
significant negative relationship with state shame (SSGS Shame), r = -.17, p < .05, such 
that lower perceived social support was indicative of higher reported state shame. When 
social support was further broken down into subscale components, perceived 
Emotional/Informational Support (MOS Emotional/Informational) evidenced a 
significant negative relationship with shame (r = -.20, p < .01), as did perceived Positive 
Social Interactions (r = -.21, p < .01) and perceived Affectionate Support (r = -.18, p < 
.05). Of the MOS subscales, only the subscale measuring Tangible Social Support 
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(MOS Tangible) did not exhibit a significant negative correlation with shame (SSGS 
Shame). 
Hierarchical Multiple Regression Analysis    
 A hierarchical multiple regression model was utilized to examine the variance in 
state shame (i.e., SSGS Shame subscale) accounted for by illness invalidation in the 
form of lack of understanding (i.e., I*3 Lack of Understanding subscale). Since 
correlation analyses revealed significant relationships between select demographic 
variables (i.e., income and length of time since symptom onset) and the criterion 
variable (i.e., SSGS Shame), these demographic variables were entered into the first 
step of the regression model in order to control for their effects on SSGS Shame. 
Subsequently, I*3 Lack of Understanding was entered into the second step, and the 
MOS Overall Support Index was entered into the third step. Finally, the interaction 
between I*3 Lack of Understanding and MOS Overall Support Index was entered into 
the fourth step.  
As noted in Table 4 (Appendix A), the total variance in scores explained by the 
overall regression model was not significant. Annual income and length of time since 
symptom onset explained 6.8% of the variance in state shame at Step 1 of the model, 
achieving significance, F (2, 111) = 5.13, p < .01, and evidencing a small effect size 
(Cohen, 1988). Illness invalidation in the form of Lack of Understanding (I*3 Lack of 
Understanding subscale) did not significantly explain variance in the second step, and 
the MOS Overall Support Index did not have a significant main effect on SSGS Shame 
scores in the third step. The interaction term (I*3 LOU x MOS Overall Support Index) 
was entered at Step 4, but was not significant.  
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Chapter Five 
Discussion 
Qualitative studies have indicated that individuals with ME/CFS frequently 
experience illness invalidation (Asbring & Narvanen, 2002; Dickson, Knussen, & 
Flowers, 2007; Dickson, Knussen, & Flowers, 2008), with associated feelings of shame 
and of experiencing their identities as questioned and no longer legitimate (Larun & 
Malterud, 2007). Prior to this study, however, there have been no known peer-reviewed 
quantitative research studies measuring the relationship between illness invalidation and 
shame among individuals with ME/CFS.  
Based on existing qualitative research, the current study hypothesized that there 
would be a positive and significant relationship between perceived illness invalidation 
(i.e., I*3) and experiences of state shame among individuals with ME/CFS (i.e., Shame 
subscale of SSGS). Data analysis partially supported this hypothesis, in that illness 
invalidation in the form of lack of understanding exhibited a significant positive 
correlation with experiences of shame. However, illness invalidation in the form of 
discounting was not significantly related to shame. 
The correlation between illness invalidation in the form of lack of understanding 
and experiences of shame is in alignment with existing qualitative research indicating 
that discussing one’s illness within the context of an invalidating environment may lead 
to internalized shame (Myers, 2004), particularly in relation to the perception of “being 
wrong in one’s definition of reality” (Ware, 1992, p. 347). Qualitative research has 
found that individuals with ME/CFS experienced particular difficulties stemming from 
others not understanding the fluctuations in ME/CFS symptoms or the physical and 
social ramifications of managing the illness (Larun & Malterud, 2007). Similarly, 
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patients have reported that their partners did not understand the consequences of their 
symptoms, such as limitations in being able to predict whether they would feel well 
enough to participate in planned activities (Dickson, Knussen, & Flowers, 2007). 
Further, individuals with ME/CFS have revealed challenges associated with others not 
understanding that pacing themselves and conserving energy on days when they felt 
better was a necessary component of managing the disorder.  
In searching for potential ameliorative factors to counter experiences of illness 
invalidation and shame, the Stress Buffering Model (Cohen & Willis, 1985) was 
reviewed as a possibly helpful theoretical framework. The Stress Buffering Model 
suggests that social support moderates the emotional effects of negative experiences and 
facilitates increased wellbeing (Cohen & Wills, 1985). Existing research appears to 
support the Stress Buffering Model, with evidence across multiple studies indicating the 
emotional benefits of social support to patients with health concerns (e.g., Kool et al., 
2012; Nenova, DuHamel, Zemon, Rini, & Redd, 2013; Zabalegui, Cabrera, Navarro, & 
Cebria, 2011).  
In keeping with the Stress Buffering Model, qualitative research has indicated 
the benefits of social support in counteracting the emotional impact of illness 
invalidation (Travers & Lawler, 2008). Specific social supports that were indicated as 
useful included: receiving help, acquiring information, and experiencing interpersonal 
safety. Additionally, individuals with ME/CFS described these social experiences as 
contributing to the reclamation of valuable aspects of the self.   
Thus, the second hypothesis of the study predicted that social support would 
moderate the relationship between illness invalidation and state shame, with increases in 
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social support leading to decreases in shame. A hierarchical regression was utilized to 
evaluate the relationships between variables. However, results of the overall model 
were not significant. Thus, the hypothesis was not supported in this sample.  
In assessing the seeming discrepancies between the results of the current study 
and existing qualitative research on experiences of illness invalidation, shame, and 
social support among individuals with ME/CFS, it is important to note that the 
relational aspect of qualitative research may create a more inviting milieu in which to 
divulge one’s experiences of illness invalidation and shame than that found in 
quantitative research conducted online. Thus, it may be that the format in which 
research is conducted contributes to differences between qualitative and quantitative 
research participants’ willingness to reveal experiences of illness invalidation and 
shame.   
While this sample was relatively well-educated, nearly half of participants 
(42.7%) reported annual incomes of $29,000 per year or less. Roughly half of 
participants (47.6%) reported being without employment, and 45.9% indicated 
disability status. It may be that the symptom composite of ME/CFS contributes to 
impaired ability to work, which may lead to unemployment and/or disability status. The 
impact of loss of employment and/or disability status may lead to lower income, despite 
educational qualifications. 
In the current study, income evidenced a significant positive relationship with 
overall social support, as well as with the majority of the social support subcomponents, 
including positive social interactions, affectionate support, emotional/informational 
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support, and tangible support. Thus, as income increased, these components of social 
support, as well as overall social support, also increased.  
The indications that income and overall social support were positively related 
may reflect broader classist ideas within the culture that place greater value on 
individuals with higher financial worth than upon individuals of lower socioeconomic 
status (SES). This may account for individuals with lower income receiving less social 
support in the form of affectionate support, positive social interactions, and 
emotional/informational support. Additionally, it may be that individuals from lower 
SES have less financial resources for engaging in positive social interactions (e.g., less 
money to hire a babysitter to go to events with friends, less funds for going out to 
restaurants with others, etc.). Further, in regard to informational support, it may be that 
individuals with higher incomes have increased access to educated and knowledgeable 
individuals who can offer them helpful information, as well as better access to advanced 
medical care and specialists. Finally, individuals with greater income may have 
increased financial capacity to pay for individuals to provide tangible support services, 
such as housekeepers, home health care, individuals to run errands, etc. 
The results of this study also indicated a significant negative relationship 
between shame and income among individuals with ME/CFS, indicating that 
participants with higher income were more likely to report lower levels of state shame. 
Or, stated another way, the trend was that individuals with lower income were more 
likely to report increased levels of shame. These results may point to the 
intersectionality of illness-related shame and class-related experiences of shame. This 
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intersectionality may be summed up in the words of Scambler (2006), who wrote the 
following regarding health-related shame:  
…the disadvantage sometimes accruing to those regarded as shameful through  
stigmatization is more often than not mixed in with, even secondary to, 
exploitation and oppression. It is empirically rare for an individual to be simply 
stigmatized or exploited  or oppressed…. (p. 292) 
An additional finding of this study was that symptom severity was significantly 
and positively related to experiences of illness invalidation in the form of discounting. 
These results may reflect trends found in other research, indicating that chronicity, 
ambiguity, and invisibility of symptoms may be particularly related to illness 
invalidation (Dickson, Knussen, & Flowers, 2007; Johnson & Johnson, 2006; Kool, 
Middendorp, Boeije, & Geenen, 2009). This relationship between symptom severity and 
illness invalidation in the form of discounting is likely to produce particular difficulties 
for persons needing to negotiate necessary illness-related adjustments in work, familial, 
or social roles. As Chrisman (1977) noted, “Illness-related shifts in role behavior imply 
a ‘bargaining’ process in which modified rights and obligations are established with 
others in the social environment” (p. 357). The lack of visible symptoms in ME/CFS 
may create increased difficulties for patients who are attempting to maintain 
modifications to their previous roles, while experiencing discounting of their illness 
experience from the environment.  
In keeping with other studies involving individuals with ME/CFS, the 
overwhelming majority of participants in this study were female, supporting the idea 
that females appear to be at greater risk of developing ME/CFS. Previous research has 
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indicated that females in the United States are at least two to three times more likely to 
experience ME/CFS symptoms than males (e.g., Bierl et al., 2004; Furberg et al., 2005; 
Jason et al., 2009), and females constituted the majority of participants in large studies 
in Sweden (Sullivan et al., 2005) and Iceland (Lindal et al., 2002), as well.  
A valuable question that might be raised pertains to whether a link exists 
between the gendered nature of ME/CFS and its association with illness invalidation. 
Mik-Meyer (2011) noted the gender biases in medical care as follows: 
In this case a man’s illness story appears normal whereas a woman’s illness 
story is an exotic mystery. The thinking seems to be that she might not, like ill 
men, have the pain she describes. (p. 35) 
Indeed, consideration of the gendered nature of ME/CFS, as well the prolific participant 
reports of illness invalidation across multiple qualitative research studies, raise 
important questions as to the political role of gender in association with this illness. 
The majority of participants in this study identified as Caucasian, which appears 
consistent with previous research indicating that ME/CFS symptoms have been found to 
occur at a significantly higher rate in Caucasians than in individuals of other racial 
backgrounds (Bierl et al., 2004). Indeed, CDC prevalence results indicated that 98% of 
individuals with ME/CFS were Caucasian (CDC, 1997).  
The current study makes a meaningful contribution to the scholarly literature, in 
that the construct of illness invalidation is relatively new to consideration in health 
psychology, and little quantitative research has been conducted in this area. It appears 
that, to date, there have been no peer-reviewed quantitative studies published that 
evaluate experiences of illness invalidation in the ME/CFS population.  
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An additional beneficial outcome of the current study was that the Illness 
Invalidation Inventory (Kool et al., 2010) was found to be a reliable measure for use 
with individuals with ME/CFS. Use of the I*3 had previously been limited to 
populations having rheumatic disorders. However, the results of the current study 
suggest that the instrument may be utilized in research with individuals who have 
ME/CFS, as well. 
Limitations  
Limitations of the current study include use of a convenience snowball sampling 
method to recruit participants. While a strength of this method is that it allowed for 
recruitment from a wide pool of individuals with ME/CFS, including those who may 
not currently participate in medical or counseling services, use of this method limits the 
generalizability of results. Additionally, posts of the survey link to internet sites 
sometimes prompted online discussion of the study by participants, and it is possible 
that such discussions may have biased responses of subsequent participants.  
Additionally, it is possible that participant response bias played a role in the 
current results. Although the I*3 contains both positively and reverse-scored items, all 
positively-scored items load on the Discounting subscale, while all reverse-scored items 
load on the Lack of Understanding scale. Given that only the Lack of Understanding 
subscale correlated with SSGS Shame, it is conceivable that systematic response bias 
contributed to the results.     
Another potential limitation is that individuals with more severe or limiting 
symptoms may have elected not to begin the survey. For example, individuals with 
more severe or limiting symptoms may have been less likely to participate in the 
survey, due to experiences of malaise, debilitating fatigue, or cognitive fog. Thus, there 
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may be a subset of the ME/CFS population whose experiences are not adequately 
reflected in this study. 
Recommendations for Future Research 
Future online research involving individuals with ME/CFS should include 
demographic questions regarding country of residence, in order to better delineate the 
generalizability of results. Given that lack of understanding evidenced a significant 
correlation with state shame, while discounting did not, future research should focus on 
the specific components of illness invalidation that may contribute to emotional distress 
for individuals with ME/CFS. 
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Appendix A 
Tables 
Table 1 
Demographic Variables 
            
Variable   M SD  Range  % N  
 
Age    45.5 11.12  18-64  -- 137 
Gender 
    Female   -- --  --  68.1 126 
    Male   -- --  --    6.5   12 
    Other   -- --  --      .5     1 
    No Response  -- --  --  24.9   46 
 
Race/Ethnic Identity 
 Caucasian  -- --  --  64.9 120 
 Native American/ -- --  --    0.5     1  
 American Indian       
 African Origin  -- --  --    0.5     1 
 Asian Origin  -- --  --    0.5     1 
 Other   -- --  --    8.1   15 
 No Response  -- --  --  25.4   47 
 
Marital Status 
 Married -- --  --  37.3 69  
 Single   -- --  --  18.4 34 
 Divorced  -- --  --  11.4 21 
 Widowed  -- --  --      .5   1 
Other   -- --  --    7.6 14 
 No Response  -- --  --  24.9 46 
Education 
 College Degree -- --  --  45.5 84 
 Some College  -- --  --  14.1 26 
 Vocational Training -- --  --    7.6 14 
 High School  -- --  --  10.3 19 
 Junior High/  -- --  --    1.6   3 
 Middle School 
 Other   -- --  --    3.2   6 
 No Response  -- --  --  17.3 32  
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Table 2 
 
Reliability, Means, and Standard Deviations Table for Variables 
 
            
Variable     M  SD  N  
 
1. I*3 LOU   .88  3.19  .64  159 
2. I*3 Discounting  .85  2.94  .75  159 
3. SSGS Shame  .80  11.83  4.97  138 
4. MOS OSI   .96  2.94  .91  144 
5. MOS Emot/Inform  .93  2.83  .97  144 
6. MOS Affectionate  .92  3.43  1.25  144 
7. MOS PSI   .89  2.93  .99  144 
8. MOS Tangible  .87  2.81  1.11  144 
            
Note. I*3 LOU = Illness Invalidation Inventory, Lack of Understanding Subscale – higher scores suggest 
higher levels of perceived illness invalidation in the form of lack of understanding. I*3 Discounting = 
Illness Invalidation Inventory, Discounting Subscale – higher scores suggest higher levels of perceived 
illness invalidation in the form of discounting. SSGS Shame = State Shame and Guilt Scale, Shame 
Subscale – higher scores suggest higher levels of state shame. MOS OSI = Medical Outcomes Study 
Social Support Survey, Overall Support Index – higher scores suggest higher levels of perceived overall 
social support. MOS Emot/Inform = Medical Outcomes Study Social Support Survey, Emotional/ 
Informational Support Subscale – higher scores suggest higher levels of perceived emotional/ 
informational social support. MOS Affectionate = Medical Outcomes Study Social Support Survey, 
Affectional Support Subscale – higher scores suggest higher levels of perceived affectionate social 
support. MOS PSI = Medical Outcomes Study Social Support Survey, Positive Social Interaction 
Subscale – higher scores suggest higher levels of perceived positive social interactions. MOS Tangible = 
Medical Outcomes Study Social Support Survey, Tangible Support subscale – higher scores suggest 
higher levels of perceived tangible social support. 
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Table 3 
 
Pearson’s Bivariate Correlations of Variables 
__________________________________________________________________________________________________________    
Variable     1   2   3   4   5   6   7  8  9               10           
1. Income     --- .07 -.19* .07 .00 .26** .21* .27**     .33**      .17*     
2. Time Symptomatic              --- -.20* .13 .04 .00 .03 -.02          -.01        -.05 
3. SSGS Shame     --- .11 .15* -.17* -.17*  -.18*     -.20*     -.01 
4. I*3 Discounting     --- .61** --.41**   -.40** -.43**  -.23** -.35** 
5. I*3 Lack of Understanding        --- -.49**    -.52**      .53** -.305** -.369** 
6. MOS Overall Support Index        ---   .93**     .86** .82** .822** 
7. MOS Emotional/Informational          ---        .73** .68** .71**  
8. MOS Affectionate          ---       .75**     .60**  
9. MOS Positive Social Interaction                     ---      .54**     
10. MOS Tangible               ---
______________________________________________________________________________________________   
Note. Income = Annual Income; Time Symptomatic = Length of time since symptom onset; SSGS Shame = State 
Shame and Guilt Scale, Shame Subscale – higher scores suggest higher levels of state shame. I*3 Discounting = 
Illness Invalidation Inventory, Discounting Subscale – higher scores suggest higher levels of perceived illness 
invalidation in the form of discounting.  I*3 Lack of Understanding = Illness Invalidation Inventory, Lack of 
Understanding Subscale – higher scores suggest higher levels of perceived illness invalidation in the form of lack of 
understanding. MOS, Overall Support Index = Medical Outcomes Study Social Support Survey, Overall Support 
Index – higher scores suggest higher levels of perceived overall social support. MOS Emotional/Informational = 
Medical Outcomes Study Social Support Survey, Emotional/Informational Support Subscale – higher scores suggest 
higher levels of perceived emotional/informational social support. MOS Affectionate = Medical Outcomes Study 
Social Support Survey, Affectional Support Subscale – higher scores suggest higher levels of perceived affectionate 
social support. MOS Positive Social Interaction = Medical Outcomes Study Social Support Survey, Positive Social 
Interaction Subscale – higher scores suggest higher levels of perceived positive social interactions. MOS Tangible = 
Medical Outcomes Study Social Support Survey, Tangible Support subscale – higher scores suggest higher levels of 
perceived tangible social support. *p  < .05. **p  < .01.  
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Table 4 
 
Hierarchical Multiple Regression Analysis for Variables  
 
Note. Income = Annual Income; Symptom Duration = Length of time since symptom onset; I*3 LOU = 
Illness Invalidation Inventory, Lack of Understanding; SSGS Shame = State Shame and Guilt Scale, 
Shame Subscale. MOS OSI = Medical Outcomes Study Social Support Survey, Overall Support Index. 
**p  < .01. 
 
 
 
 
 
 
 
 
 
Appendix B 
IV  Step R2  ∆R2  F Change df  B  SE B  ß  
Income  
 
 
Symptom 
Duration 
 
 
1 
 
 
1 
 
 
 
 
.085 
 
 
.085 
 
 
 
.068 
 
 
.068 
 
 
5.128** 
 
 
5.128** 
 
 
 
(2, 111)  
 
 
(2, 111)  
 
 
 
-.066 
 
 
-.061 
 
 
 
.036 
 
 
.024 
 
 
 
 
-.169 
 
 
-.228** 
 
 
I*3 LOU 2  .097 .073 1.546 (1, 110) .012 .010 .114 
MOS OSI 3 .105 .072 .982 (1, 109)  -.006 .006 -.096 
I*3 LOU X 
MOS OSI   
 
4 .106 .065 .100 (1, 108)  .000 .001 .753 
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Appendix C 
Instruments 
 
Demographic Questionnaire 
 
1. Do you suffer from chronic fatigue syndrome/myalgic encephalomyelitis? 
a. Yes  b. No 
 
[If No, proceed to Exit Page. If Yes, proceed to Question 2.] 
 
Page 1 
In order to complete this study, I would like to know more about you. The information 
that you provide will not be used to identify you in any way.  
 
2. Gender:  a. Female  b. Male  c. Other  
 
3. Age: [drop-down with ages from 18-64] 
 
4. What is the highest level of education that you have completed?  
a. Junior high/middle school 
b. High school 
c. Some college 
d. Vocational training 
e. Associate’s degree 
f. Bachelor’s degree or equivalent professional degree 
g. Master’s degree or equivalent professional degree 
h. Doctorate degree or equivalent professional degree 
i. Other (please specify): _________________________ 
 
5. Marital Status:    a. Single b. Married c. Divorced   d. Widowed     e. Other: 
________ 
 
6. How would you describe your race/ethnicity? 
a. African origin 
b. American Indian/Native American 
c. Asian origin 
d. Biracial or Multiracial 
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e. Caribbean origin 
f. Caucasian 
g. Latino/a 
h. Middle Eastern origin 
i. Native Hawaiian or Pacific Islander origin 
j. Other (please specify) _____________________ 
 
7. What is your annual household income? 
a. Under $20,000 
b. $20,000-$29,000 
c. $30,000-39,000 
d. $40,000-$49,000 
e. $50,000-$59,000 
f. $60,000-$69,000 
g. $70,000-$79,000 
h. $80,000-$89,000 
i. $90,000-$99,000 
j. $100,000 + 
 
8. Do you have children? 
[If Yes, proceed to Question 9. If No, proceed to Question 11.] 
Page 2 
9. How many children do you have? [drop-down with numbers 1-10+] 
 
10. How many of your children live with you? [drop-down with numbers 1-10+] 
Page 3 
11. Are you disabled?  a. Yes b. No 
[If Yes, proceed to Question 12. If No, proceed to Question 13.]  
 
Page 4 
12. What diagnosis or diagnoses led to your disability status? 
_____________________ 
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Page 5 
Please answer the following questions about your experiences with chronic 
fatigue/myalgic encephalomyelitis (ME/CFS). 
13. How long has it been since you first began suffering from symptoms of chronic 
fatigue syndrome/ myalgic encephalomyelitis?  
a. Less than 1 year 
b. 1 year 
c. 2 years 
d. 3 years 
e. 4 years 
f. 5 years 
g. 6 years 
h. 7 years 
i. 8 years 
j. 9 years 
k. 10 years 
l. 11-20 years 
m. 30+ years 
 
14. Were you diagnosed with chronic fatigue syndrome and/or myalgic 
encephalomyelitis by a medical care provider?  
a. Yes   b. No 
[If Yes, proceed to Question 15. If No, proceed to Question 18.] 
Page 6 
15. Who diagnosed you with chronic fatigue syndrome/ myalgic encephalomyelitis? 
a. General medical doctor/Family medical doctor 
b. Medical doctor who is a specialist in a specific area of medicine  
c. Physician’s assistant 
d. Nurse practitioner 
e. Other (please specify) ______________________ 
[If “Medical doctor who is a specialist in a specific area of medicine,” proceed 
to Question 16. If any other response, proceed to Question 17.] 
Page 7 
16. What was the specific specialty area of the medical doctor who diagnosed you 
with CFS/ME? ______________ 
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Page 8 
17. How long did you suffer from the symptoms of CFS/ME before receiving a 
diagnosis? (Please list in years and months) _____________ 
 
18. Are you currently under the care of a medical doctor who is a specialist in a 
specific area of medicine? 
 
a. Yes  
b. No 
[If “Yes,” proceed to Question 19. If “No,” proceed to Question 21.] 
Page 9 
19. What was the length of time from the onset of your symptoms to your receiving 
care from a medical doctor who is a specialist? (Please list in years and months) 
___________________ 
 
20. What is the specific specialty area of the medical doctor who is currently 
providing care for your ME/CFS? ______________ 
Page 10 
21. How limited are you by your ME/CFS symptoms?  (Note: 0 indicates absence of 
limitations, and increasingly higher numbers indicate increased limitations by 
symptoms) 
 
[response on slider from 0-100] 
 
22. How would you rate the severity of your current ME/CFS symptoms? (Note: 0 
indicates absence of symptoms, and increasingly higher numbers indicate 
increased severity of symptoms) 
[response on slider from 0-100] 
23. How would you describe your current symptom status? 
 
a. Intense symptoms and/or many problematic symptoms 
b. Moderate symptoms 
c. Mild symptoms 
d. Symptoms in remission 
 
24. What have you found most helpful in managing your physical symptoms? 
__________________________________ 
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25. What have you found most helpful in emotionally coping with your illness? 
___________________________________ 
 
26. If you were to give advice to someone else with ME/CFS, what advice would 
you share? _____________________________________ 
 
27. Are you involved in a support group for individuals with ME/CFS? 
 
a. Yes 
b. No 
 
[If “Yes,” proceed to Question 28. If “No,” proceed to Question 29.] 
 
28. Please describe the type of support group in which you are involved. 
___________________________ 
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Illness Invalidation Inventory (3*I) 
 
© 2008, Kool, van Middendorp & Geenen 
 
We are interested in how others react to people who have health problems or an illness. 
Each of the sections below refers to different people in your life. We would like you to 
rate how often during the past year each person or category of people reacted toward 
you in the way described. After each statement, circle the number between 1 (never) 
and 5 (very often) to indicate how often they reacted toward you that way. 
 
The questionnaire has five sections, and you will rate the same reactions a number of 
times, but referring to different people. If a particular section does not apply to you, you 
may skip that part of the questionnaire and go on to the next section. Remember, rate 
the items with respect to how others reacted toward you as a person who has health 
problems or an illness. 
Section 1: Spouse or partner    
 
If you are single (not married, a widow/widower, or without a steady partner) then skip 
Section 1 and go directly to Section 2. 
My spouse or partner…………… Never Seldom 
Some-
times 
Often 
Very 
often 
1.1 ….finds it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
1.2 ….thinks I should be tougher. 1 2 3 4 5 
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1.3 ….takes me seriously. 1 2 3 4 5 
1.4 ….gives me unhelpful advice. 1 2 3 4 5 
1.5 ….understands the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
1.6 ….makes me feel like I am an          
exaggerator. 
 
1 2 3 4 5 
1.7 ….thinks I can work more than I do. 1 2 3 4 5 
1.8 ….gives me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
 
Section 2: Family 
For example, children, parents, brothers, sisters, uncles, aunts, grandparents, in-laws. 
 
My family……… Never Seldom 
Some-
times 
Often 
Very 
often 
2.1 ….finds it odd that I can do much 
more     on some days than on other 
days. 
1 2 3 4 5 
2.2 ….thinks I should be tougher. 1 2 3 4 5 
2.3 ….takes me seriously. 1 2 3 4 5 
2.4 ….gives me unhelpful advice. 1 2 3 4 5 
2.5 ….understands the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
2.6 ….makes me feel like I am an 
exaggerator. 
1 2 3 4 5 
2.7 ….thinks I can work more than I do. 1 2 3 4 5 
2.8 ….gives me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
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Section 3: Medical professionals  
For example, your primary care physician, medical specialist, physical therapist, and 
other medical professionals. (Do not include your employer’s company physician). 
  
Medical professionals ..... Never Seldom 
Some-
times 
Often 
Very 
often 
3.1 ….find it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
3.2 ….think I should be tougher. 1 2 3 4 5 
3.3 ….take me seriously. 1 2 3 4 5 
3.4 ….give me unhelpful advice. 1 2 3 4 5 
3.5 ….understand the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
3.6 ….make me feel like I am an 
exaggerator. 
 
1 2 3 4 5 
3.7 ….think I can work more than I do. 1 2 3 4 5 
3.8 ….give me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
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If you did not have paid or unpaid employment in the past year, then skip this Section and 
go directly to Section 5. 
People at work…….  Never Seldom 
Some-
times 
Often 
Very 
often 
4.1 ….find it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
4.2 ….think I should be tougher. 1 2 3 4 5 
4.3 ….take me seriously. 1 2 3 4 5 
4.4 ….give me unhelpful advice. 1 2 3 4 5 
4.5 ….understand the consequences of 
my   
     health problems or illness. 
1 2 3 4 5 
4.6 ….make me feel like I am an 
exaggerator. 
 
1 2 3 4 5 
4.7 ….think I can work more than I do. 1 2 3 4 5 
4.8 ….give me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
 
 
 
 
 
 
Section 4:  Work environment   
For example, your co-workers and boss. (Do not include your employer’s company 
physician).  
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If you did not have any interactions with these providers, you may skip this Section.  
People in social services…….  Never Seldom 
Some-
times 
Often 
Very 
often 
5.1 ….find it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
5.2 ….think I should be tougher. 1 2 3 4 5 
5.3 ….take me seriously. 1 2 3 4 5 
5.4 ….give me unhelpful advice. 1 2 3 4 5 
5.5 ….understand the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
5.6 ….make me feel like I am an 
exaggerator. 
1 2 3 4 5 
5.7 ….think I can work more than I do. 1 2 3 4 5 
5.8 ….give me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
 
 
 
 
 
 
 
Section 5 : Social services  
For example, your employer’s company physician, work-reintegration or vocational 
rehabilitation staff, unemployment and other government agencies, organizations for 
care at home, general government workers and health insurance companies. 
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The State Shame and Guilt Scale 
(Marschall, Sanftner, & Tangney, 1994) 
 
The following are some statements which may or may not describe how you are feeling 
right now.  Please rate each statement using the 5-point scale below.  Remember to rate 
each statement based on how you are feeling right at this moment. 
 
  
                                         Not feeling        Feeling          Feeling          
                                            this way           this way          this way 
                                                 at all           somewhat      very strongly 
 
1.  I feel good about myself. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
2.  I want to sink into the floor and disappear. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
3. I feel remorse, regret. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
4.  I feel worthwhile, valuable. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
5.  I feel small. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
6.  I feel tension about something I have done. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
7.  I feel capable, useful. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
8.  I feel like I am a bad person. 1 ------- 2 ------- 3 ------- 4 ------- 5 
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9. I cannot stop thinking about something  
      bad I have done. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
10. I feel proud. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
11. I feel humiliated, disgraced. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
12. I feel like apologizing, confessing. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
13. I feel pleased about something I have done. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
14. I feel worthless, powerless.  1 ------- 2 ------- 3 ------- 4 ------- 5 
 
15. I feel bad about something I have done.  1 ------- 2 ------- 3 ------- 4 ------- 5
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Medical Outcomes Study Social Support Survey 
(Sherbourne & Stewart, 1991) 
 
Next are some questions about the support that is available to you. 
 
People sometimes look to others for companionship, assistance, or other types of 
support. How often is each of the following kinds of support available to you if you 
need it?  
 
None of the time    A little of the time    Some of the time    Most of the time    All of 
               the time 
1        2      3   4      5 
 
1) Someone to help you if you were confined to bed…. 
2) Someone you can count on to listen to you when you need to talk…. 
3) Someone to give you good advice about a crisis…. 
4) Someone to take you to the doctor if you needed it…. 
5) Someone who shows you love and affection…. 
6) Someone to have a good time with…. 
7) Someone to give you information to help you understand a situation…. 
8) Someone to confide in or talk to about yourself or your problems…. 
9) Someone who hugs you…. 
10) Someone to get together with for relaxation…. 
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11) Someone to prepare your meals if you were unable to do it yourself…. 
12) Someone whose advice you really want…. 
13) Someone to do things with to help you get your mind off things…. 
14) Someone to help with daily chores if you were sick…. 
15) Someone to share your most private worries and fears with…. 
16) Someone to turn to for suggestions about how to deal with a personal 
problem…. 
17) Someone to do something enjoyable with…. 
18) Someone who understands your problems…. 
19) Someone to love and make you feel wanted…. 
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Appendix D 
Prospectus 
 
Impact of Social Support on the Relationship between Illness Invalidation  
and Shame Among Sufferers of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 
 
 
 
Elizabeth Kendrick, M.S. 
University of Oklahoma 
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Abstract 
The current study will examine the relationship between illness invalidation and shame 
in a sample of adults with myalgic encephalomyelitis/chronic fatigue syndrome. It is 
expected that this relationship will be moderated by perceived social support, 
particularly in the form of esteem support. Results are expected to support the Stress 
Buffering Model. 
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Chapter One 
Introduction 
Myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome 
(CFS), is a complex and poorly understood disorder that affects an estimated 2.2 million 
Americans (Bierl et al., 2004). ME/CFS appears to involve dysregulation of the immune 
system (e.g., Gaab et al., 2005; Panerai et al., 2002; White et al., 2010), the endocrine 
system (e.g., Cleare, Blaire, Chambers, & Wessely, 2001; White, Light, Hughen, 
VanHaitsma, & Light, 2012), the neuroendocrine system (e.g., Antoni, et al., 2010; 
Maloney, Boneva, Nater, & Reeves, 2009), and the central nervous system (e.g., de 
Lange et al., 2004; Siemionow, Fang, Calabrese, Sahgal, & Yue, 2004). Patients 
experience debilitating fatigue, sleep dysfunction, post-exertional malaise, slowed 
cognitive processing, hypersensitivity to sensory stimulation, and other symptoms 
(Carruthers et al., 2003; Fukuda et al., 1994).  
Despite physiological abnormalities in ME/CFS, the disorder is poorly 
understood and is frequently met with contest, doubt, and suspicion from medical and 
lay persons (Bayliss et al., 2014; Travers & Lawler, 2008). Individuals with ME/CFS 
have reported experiencing illness invalidation by having their illness experiences 
discounted, minimized, or dismissed by medical professionals and significant others 
(Johnson & Johnson, 2006; Larun & Malterud, 2007). Further, individuals with 
ME/CFS have reported feelings of shame associated with invalidation of their 
symptoms (Larun & Malterud, 2007). The Stress Buffering Model, with its proposal 
that social support counteracts threats to self-concept during periods of elevated stress 
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(Cohen & Wills, 1985), provides a rationale that social support may play an 
ameliorative role in reducing shaming effects of illness invalidation. 
Despite qualitative studies indicating that individuals with ME/CFS commonly 
experience illness invalidation (Asbring & Narvanen, 2002; Dickson, Knussen, & 
Flowers, 2007; Dickson, Knussen, & Flowers, 2008), the construct is relatively new to 
consideration in health psychology, and little quantitative research has been conducted 
in this area. Additionally, the majority of research on illness invalidation has been 
limited to studies of patients with rheumatic diseases (Kool, van Middendrop, Lumley, 
Bijlsma, & Geenen, 2012). Therefore, this study aims to elucidate the impact of illness 
invalidation and social support upon shame experiences among ME/CFS sufferers. 
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Chapter Two 
Literature Review 
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 
Myalgic Encephalomyelitis has been classified in the World Health 
Organization’s International Classification of Diseases as a neurological disease 
(Carruthers & van de Sande, 2005). While fatigue is often highlighted in ME/CFS, it is 
only one of multiple symptoms within the disorder. Individuals with ME/CFS 
experience post-exertional malaise, slowed cognitive processing, hypersensitivity to 
sensory stimulation, sleep dysfunction, and other symptoms (Carruthers et al., 2003; 
Fukuda et al., 1994). Centers for Disease Control and Prevention (CDC; 1997) 
surveillance results found that 95% of patients reported neurocognitive complaints, 81% 
reported sleep disturbance, 80% reported fever and/or chills, and 78% reported myalgia. 
The most frequently reported ME/CFS symptom found in data from the Mid-Atlantic 
Twin Study (Furberg, Olarte, Afari, Goldberg, Buchwald, & Sullivan, 2005) and in the 
Wichita, Kansas population-based study was unrefreshing sleep (Nisenbaum, Jones, 
Unger, Reyes, & Reeves, 2003).    
The term fatigue does not adequately describe the debilitating exhaustion, 
malaise, feelings of heaviness, and lightheadedness that individuals with ME/CFS 
experience (Carruthers & van de Sande, 2005). Markedly different from ordinary 
fatigue, in which an individual experiences loss of energy that is easily restored by rest, 
individuals with ME/CFS typically experience at least a 50% reduction in activity levels 
as a result of incapacitating fatigue. These levels of fatigue may require an individual to 
become homebound and/or dependent upon others for care.  
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Research comparing ME/CFS patients with multiple sclerosis (MS) patients 
found that ME/CFS patients scored higher on measures of fatigue than individuals with 
MS (Taillefer, Kirmayer, Robbins, & Lasry, 2002). While both groups reported similar 
scores on physical functioning, ME/CFS patients scored significantly higher on 
measures of the impact of their illness on their employment and daily activities.  
 Cognitive fatigue is often a component of ME/CFS as well, with physical or 
cognitive demands resulting in slowed cognitive processing, decreased coherence, and 
struggles with retrieving information and/or words (Carruthers & van de Sande, 2005). 
This cognitive fatigue is often referred to as cognitive fog, exhibited by impaired 
concentration, difficulties sustaining attention, forgetfulness, confusion, and slowed 
reaction time. Processing of complex information may be impaired, and during 
incidences of over-fatigue, individuals may display dyslexia. 
 Individuals with ME/CFS also report experiencing hypersensitivity to sensory 
stimuli within their environment (Carruthers & van de Sande, 2005). Sounds, lights, 
temperature extremes, and other sensory experiences may become overwhelming. 
When multiple sources of sensory input are present (e.g., concurrent visual and auditory 
stimuli; physical activity combined with cognitive activity; unclear situations or hurried 
environments), patients may experience difficulties with focus. Emotional overload may 
also result in a “crash,” in which the individual becomes debilitated by fatigue and has 
difficulty recovering.  
Debate over the Diagnostic Label 
 The label chronic fatigue syndrome has been commonly associated with this 
disorder; however, patient advocate groups believed that use of fatigue in the label 
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emphasizes only one dimension of a complex disorder (Carruthers et al., 2011) and 
contributes to public perception that the disorder is entirely psychological in nature 
(Arnett & Clark, 2012). As research has begun to increasingly elucidate the 
physiological pathology underlying the disorder, it has been considered more 
appropriate and accurate to call the illness myalgic encephalomyelitis (Carruthers et al., 
2011). This label is believed to be more consistent with the World Health 
Organization’s classification of the illness as a neurological condition.  
 The change in the disorder’s name has not come without debate, however. 
Fukuda and colleagues (1994) asserted that no name change should be made, due to the 
public and medical awareness associated with the existing label and due to confusion 
that might result from changing the name. Further, Fukuda and colleagues argued that 
no label change should occur until the etiology and processes of the disorder were better 
understood. Huibers and Wessely (2006) maintained that chronic fatigue syndrome was 
preferable because this term does not infer etiology and because it allows for a 
multifactorial explanation.  
 Others have argued that chronic fatigue syndrome and myalgic 
encephalomyelitis are separate, but related, disorders, with divergent etiologies (Jason, 
Helgerson, Torres-Harding, Carrico, & Taylor, 2003; Maes, Twisk, & Johnson, 2012). 
Some research indicated that post-exertional malaise and markers of inflammatory/ 
infectious processes differentiated ME from CFS, despite their shared characteristics 
(Maes, Twisk, & Johnson, 2012). As such, the argument has been made that the two 
diagnoses should not be subsumed under one label, but should be distinguished from 
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each other. Furthermore, Jason et al. (2003) posited that ME/CFS may, in fact, represent 
a cluster of distinct disease processes that have been inappropriately grouped together. 
 Given the current debate over the diagnostic label, many authors prefer to 
simply combine the labels into one (e.g., ME/CFS; Arnett & Clark, 2012). In the current 
study the disorder will be referred to as ME/CFS.  
Etiology  
The etiology of ME/CFS continues to be poorly-understood and is likely 
complex (Bierl et al., 2004). Existing research suggests the involvement of 
inflammatory processes (Fulle et al., 2000; Maes, Mihaylova, Kubera, & Bosmans, 
2007; Pall & Satterlee, 2001; Richards, Roberts, McGregor, Dunstan, & Butt, 2000), 
alterations in gene expression (Light, , 2011), immune dysfunction (Maes, Twisk, 
Kubera, & Ringel, 2012; Masuda et al., 2002), involvement of the hypothalamic-
pituitary-adrenal (HPA; Cleare, 2004; Johnson & DeLuca, 2005; Van Den Eede, 
Moorkens, Van Houdenhove, Cosyns, & Claes, 2007), and altered levels of 
progesterone (Pearson Murphy, Abbott, Allison, Watts, & Ghadirian, 2004).  
 Inflammatory processes. In the 2000s, indications began to arise from research 
that inflammatory processes were at play in ME/CFS (Arnett & Clark, 2012). For 
example, studies found elevated oxidative stress (Fulle et al., 2000; Pall & Satterlee, 
2001; Richards et al., 2000) and decreased antioxidant power (Jason et al., 2011) in 
patients with ME/CFS. Oxidative stress occurs when there is a disruption in the 
equilibrium between the production of reactive oxygen intermediates (commonly 
known as free radicals) and antioxidant defenses, such as cellular production of 
enzymes that detoxify free radicals and repair the damage they have incurred 
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(Betteridge, 2000; Storz & Imlay, 1999). Oxidative stress results in a state of chronic 
inflammation (Jason et al., 2011). Furthermore, oxidative stress and reduced antioxidant 
capability have been found disruptive to the hypothalamic-pituitary-adrenal (HPA) axis 
(Epel et al., 2004). 
Research has found that elderly individuals with ME/CFS experienced increased 
histone deacetylase-2 (HDAC-2) activity (Jason et al., 2011). Elevated HDAC-2 
activity is typically associated with neuronal death stemming from oxidative stress, and 
HDAC-2 elevations are found in many neurological disorders. On the other hand, 
decreased HDAC-2 activity protects against neuronal death induced by oxidative stress. 
Alterations in gene expression. Research that evaluated differences in gene 
expression between individuals with ME/CFS and controls, following moderate 
exercise, found alterations in gene expression among ME/CFS patients, following 
physical activity (Light et al., 2011). Prior to exercise, gene expression did not 
differentiate patients from controls, but following exercise, ME/CFS patients evidenced 
larger increases in mRNA for seven genes. These dysregulated genes are directly 
implicated in the signaling of fatigue, as well as being involved in immunological 
activity, cellular energy, and the cardiovascular system.  Patients with the highest illness 
severity evidenced the greatest increase in gene expression, and those with the lowest 
severity displayed the least increase in gene expression. The mRNA increases in 
patients were apparent within 30 minutes of engaging in exercise and remained evident 
for at least 48 hours.  Even the most functional ME/CFS patients differed from healthy 
controls in gene expression.  
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Light and colleagues (2011) proposed that the results “might indicate that 
upstream transcription factors common to all of these genes are dysregulated and 
control these downstream genes in a pathological fashion” in ME/CFS (p. 77). This 
suggestion is particularly interesting given that all seven genes whose expression 
differed in ME/CFS patients share common transcription factors. However, it was 
alternatively noted that alterations in gene expression might result from viral infections. 
This is a relevant consideration, given evidence suggesting that ME/CFS often develops 
following viral infections, such as Epstein-Barr infection (Hickie et al., 2006; Lerner, 
Beqaj, Deeter, & Fitzgerald, 2004). 
Other research found that, compared to controls, ME/CFS patients evidenced 
significant reduction in the median expression of six genes in isolated CD19+ proteins 
on B cells (a type of white blood cell; Aspler, Bolshin, Vernon, & Broderick, 2008). 
The genetic expression of these cells is preferentially up-regulated in healthy 
individuals. CD19+ proteins on B cells play a role in immune function, and previous 
research found that CD19+ mutations were associated with antibody-deficiency 
syndrome (van Zelm et al., 2006). Two CD19+ genes (PTPRK and TSPAN3) that are 
linked with the development and adhesion of immune cells evidenced the most 
suppression (Aspler et al., 2008). PTPRK is known to be suppressed by the Epstein-
Barr virus (Flavell et al., 2007), a virus linked to the onset of ME/CFS in some patients 
(Hickie et al., 2006; Lerner et al., 2004). Additionally, the CD14+ monocyte gene set of 
ME/CFS patients was found to share significant co-expression with CD19+ B cell 
genes, indicating an immunological interaction consistent with chronic inflammation 
(Aspler et al., 2008).  
85 
 
Overall, the co-expression of immune system gene sets indicates that patients 
with ME/CFS experience immune signaling processes consistent with chronic 
inflammation mechanisms (Aspler et al., 2008).  It should be noted, however, that 
research involving the Swedish Twin Registry found no significant correlation between 
ME/CFS symptoms and zygosity of twin pairs (Evengard et al., 2005). 
Immune dysfunction. Research evidence has also suggested that inflammatory 
pathways and cell-mediated immunity (CMI) play a key role in the pathology of 
ME/CFS (Maes et al., 2012). When five immune biomarkers (plasma inerluekin -1, 
tumor necrosis factor- α, PMN-elastase, serum neopterin, and lysozyme) were 
evaluated, all immune biomarkers were significantly elevated in ME/CFS patients, 
when compared to controls. These results suggested that ME/CFS is associated with 
persistent low-grade inflammation.  
 The immune biomarker, PMN-elastase, has been found to be significantly 
increased in ME/CFS, compared to controls (Maes et al., 2012). This is of interest since 
PMN-elastase regulates inflammatory responses, via a feedback mechanism that may 
result in cyclical inflammation (Doring et al., 1986). Furthermore, PMN-elastase has 
been linked to decreased daily functioning and diminished capacity for exercise (Meeus 
et al., 2008; Nijs & de Meirleir, 2005; Nijs et al., 2005).  
Intensive research over the past two decades has evaluated the role of cytokine 
activity in the pathphysiology of ME/CFS (Arnett & Clarks, 2012). Cytokines are 
proteins, synthesized by cells, that play a role in the regulation of immunological 
responses to infection, inflammation, and injuries (Dinarello, 2000; Lyall, Peakman, & 
Wessely, 2003). Cytokines are manufactured by T cells and other cells of the immune 
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system, following immunological insult (Lyall et al., 2003). Cytokines, which serve as 
signals between cells of the immune system and other cells in the body (Lyall et al., 
2003), are involved in interactions between the immune system and the central nervous 
system, and serve to alert the brain of disease (Kapsimalis et al., 2008).  
Some cytokines assist with healing (anti-inflammatory), while others increase 
disease processes (pro-inflammatory; Dinarello, 2000). Additionally, some pro-
inflammatory cytokines, such as tumor necrosis factor, trigger manufacture of 
additional inflammatory cytokines (Chu, 2013). Pro-inflammatory cytokine-mediated 
illness behaviors consist of symptoms that include fatigue, slowed psychomotor 
activity, hyperalgesia (increased pain sensitivity), anhedonia, changes in circadian 
patterns that alter sleep, and depressive symptoms (Dinarello, 2000). When 
administered to humans, some pro-inflammatory cytokines, such as interleukin (IL)-1 
and tumor necrosis factor- α, induce fever, destruction of tissue, inflammation, myalgia, 
and sometimes shock and death (Dinarello, 2000; Janik et al., 1996).  
The majority of cytokine genes are never expressed, unless aversive events 
trigger the stimulation of their expression (Dinarello, 2000). Examples of cell stressors 
that may trigger cytokine expression include exposure to ultra-violet light, thermal 
shock, infection, and inflammation, to name a few. Incidentally, the inflammation that 
results from pro-inflammatory cytokine mediation can lead to expression of other 
previously unexpressed cytokine genes, resulting in “a cascade of gene products usually 
not produced in healthy persons” (p. 504).    
Arnett and Clark (2012) presented an excellent literature review of existing 
research on the inflammatory pathophysiology, neurological responses to inflammation, 
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cytokine-mediated illness behavior, and potential neuroimmunological interactions in 
ME/CFS. The authors proposed that ME/CFS results from a pathological variation of 
pro-inflammatory cytokine-mediated illness behavior comparable to the experiences of 
fatigue that are found in many other inflammatory disorders. The authors proposed that 
ME/CFS results from immunological responses that are “inappropriately robust or are 
of an inappropriate duration,” resulting in a symptom picture reflecting a “deranged, 
maladaptive permutation” of cytokine-mediated illness behavior (p. 304).  
Arnett and Clark (2012) also noted that the overlap between inflammatory 
cytokine-induced illness behaviors and the symptom picture of ME/CFS is pronounced 
and may point to a shared underlying mechanism. For example, cytokine-mediated 
illness behaviors may consist of symptoms that include fatigue, slowed psychomotor 
activity, hyperalgesia (increased pain sensitivity), anhedonia, changes in circadian 
patterns that alter sleep, and depressive symptoms. These cytokine-mediated illness 
behaviors share remarkable similarities with salient symptoms of ME/CFS. It is 
noteworthy that numerous studies appear to support Arnett and Clark’s (2012) 
hypothesis. Other authors have noted that the flu-like malaise that is frequently found in 
ME/CFS may reflect sickness behaviors induced by the elevated cytokines found in 
ME/CFS patients (Maes et al., 2012). In fact, some have proposed that consideration 
should be given to the prospect of treating ME/CFS with anti-inflammatory compounds 
that target cytokine processes, such as the prescription drug Anikinra (Arnett & Clark, 
2012; Maes et al., 2012). 
In related research, post-exertional malaise among individuals with ME/CFS 
was found to be significantly related to inflammatory and cell-mediated immune 
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biomarkers (Maes, Twisk, & Johnson, 2012). The cytokine network and the 
neuroendocrine system appear to act together in the regulation of sleep-wake cycles, 
with their interactions appearing to play a role in the pathogenesis of some sleep 
difficulties, such as those accompanying illness (Kapsimalis et al., 2008). Multiple 
studies indicating that sleep disorders are a prominent and problematic component of 
ME/CFS (e.g., Carruthers et al., 2003; CDC, 1997; Fukuda et al., 1994; Hickie et al., 
2009) add support to the premise that cytokine-mediated illness symptoms may be at 
play in ME/CFS.   
Natural killer (NK) cell activity has also been found to be suppressed in 
individuals with ME/CFS, when compared to healthy controls (Masuda et al., 2002). 
NK cells serve the immunological function of destroying infectious cells within the 
body. Compared to controls, ME/CFS patients were found to evidence increased 
expression of a set of four natural killer (NK) cell genes, with greatest increase in 
expression of NKG2A/C (Aspler et al., 2008). NKG2A/C plays a role in cytotoxic 
activities. (Note: Cytoxicity refers to destroying of cells, e.g., destruction of infected 
cells by lymphocytes.). Therefore, these findings were consistent with suppression of 
cytotoxic activity in ME/CFS. Patients who developed ME/CFS following an 
identifiable infection (e.g., Epstein-Barr virus infection, cytomegalovirus infection, etc.) 
had the greatest suppression of NK cell activity (Masuda et al., 2002).  
Additionally, elevated nuclear factor κB (NFκB) has been found in ME/CFS 
(Maes, Mihaylova, & Bosmans, 2007; Maes, Mihaylova, Kubera, & Bosmans, 2007). 
Nuclear factor κB (NFκB) plays a role in cellular reactions to stress, cytokines, and 
antigens (Brasier, 2006; Gilmore, 20006). Dysregulation of NFκB has been linked to 
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inflammatory processes, autoimmune disorders, and faulty immune system 
development. Increased NFκB prompts manufacture of pro-inflammatory cytokines 
(Morris & Maes, 2012).  
The research linking dysfunctional immunological response to ME/CFS has not 
been conclusive, however. In a systematic review of ME/CFS studies published from 
1996 to 2000, Lyall and colleagues (2003) found that deviations in the number, 
function, and activation markers of T cells were found in the highest-rated studies, but 
atypical levels of cytokines and abnormal numbers and functions of NK cells were 
typically not found in the highest-rated studies. The authors noted, however, that their 
results did not eliminate the potential that ME/CFS is caused, at least partially, by 
immune system dysfunction. 
HPA-axis and immune function. An increasing accumulation of research 
evidence supports the hypothesis that dysregulation of the hypothalamic-pituitary-
adrenal (HPA) axis response to stress plays an important role in ME/CFS (Cleare, 2004; 
Johnson & DeLuca, 2005; Van Den Eede et al., 2007). The HPA axis is responsible for 
regulating the functioning of the endocrine and autonomic nervous systems, as well as 
multiple pathways of the immune system (McEwen & Stellar, 1993). Research indicates 
that the HPA axis provides regulation of the immune system through regulation of 
corticoseteriod secretion and directly involves inflammatory feedback, with pro-
inflammatory cytokines modulating the hypothalamus’ release of corticotrophin 
releasing factor (Cupps & Fauci, 1982; Hench, Slocum, Polley, & Kendal, 1950). 
Progesterone. Mean levels of progesterone and all of its metabolites have been 
found to be higher in patients with ME/CFS than in age-matched healthy controls 
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(Pearson Murphy et al., 2004). Some have suggested that ME/CFS symptoms may stem 
directly from elevated progesterone levels. Freeman et al. (1993) found that 
administering micronized progesterone to healthy women resulted in increases in 
fatigue and confusions, as well as slowing of verbal recall and of ability to copy 
symbols. 
Prevalence 
 An estimated 2.2 million adults in the United States suffer from ME/CFS 
symptoms (Bierl et al., 2004). Research by the U.S. Centers for Disease (CDC) found 
that prevalence among adults over a four-year period varied from 3.8 cases per 100,000 
people to 5.2 per 100,000, based on geographical location within the country (CDC, 
1997). Data from the U.S. Mid-Atlantic Twin Registry (N = 4,591) found a 2.7% 
lifetime prevalence for ME/CFS symptoms (Furberg et al., 2005). A stratified 
community study in Chicago revealed a point-in-time prevalence rate of 2.2% (Jason et 
al., 1999), while a Wichita, Kansas study found a weighted point prevalence of 235 per 
100,000 individuals (Reyes et al., 2003). Prevalence rates for ME/CFS in Iceland were 
found to be 1.4% (Lindal, Stefansson, & Bergmann, 2002). Natural history research 
found that rates of ME/CFS remained approximately unchanged over roughly ten years 
(Jason, Porter, Hunnell, Rademaker, & Richman, 2010). 
Demographics 
Race. Research on the prevalence of ME/CFS, based on race, has yielded mixed 
results. ME/CFS symptoms have been found to occur at a significantly higher rate in 
Caucasians than in individuals of other racial backgrounds (Bierl et al., 2004), with 
CDC results indicating that 98% of patients were Caucasian (CDC, 1997). A stratified 
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community study in Chicago, however, found that Native Americans and Latinos had 
the highest prevalence rates (5.4% and 3.9%, respectively), while Asians and 
Caucasians had the lowest prevalence rates (1.0% and 1.4%, respectively; Jason et al., 
1999).   
African Americans and Latinos with chronic fatigue have reported significantly 
higher levels of fatigue following exertion than Caucasians (Jason et al., 2002). Latinos 
have also indicated significantly higher scores on cognitive difficulties associated with 
fatigue than Caucasians. 
Gender. Females appear to be at the highest risk of developing ME/CFS. 
Females in the U.S. have been found to be two to three times more likely to experience 
ME/CFS symptoms than males (Bierl et al., 2004; Furberg et al., 2005; Jason et al., 
2009). Women in Wichita, Kansas experienced 4.5 times higher rates of ME/CFS than 
males (Reyes et al., 2003). The U.S. CDC (1997) surveillance study found that 85% of 
individuals with the disorder were female. 
Research utilizing data from the Swedish Twin Registry also found that the 
majority of participants exhibiting symptoms of ME/CFS were female (64.17%; 
Sullivan et al., 2005). Women in the Swedish Twin Registry were 3.92 times more 
likely to have a 6-month prevalence of ME/CFS symptoms than men (Evengard, Jacks, 
Pedersen, & Sullivan, 2005). Further, the majority (78%) of participants with ME/CFS 
in an Icelandic prevalence study (N  = 4,000) were female (Lindal et al., 2002).  
Gender differences were found to become more pronounced as definitions of 
fatigue became more stringent (Furberg et al., 2005) and as symptoms became more 
severe (Reyes et al., 2003). Females were found to develop significantly more 
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associated symptoms and at significantly younger ages than males (Furberg et al., 
2005). Women were also found to score significantly higher on problems pertaining to 
memory, concentration, and information-processing than men (Jason et al., 2002).    
Explanations for the association between female gender and ME/CFS remain 
unknown. Some have conjectured that the relationship is likely complex and may 
include a number of factors, ranging from genetic composition to sociological issues 
related to being female (Evengard et al., 2005). For example, some have proposed that a 
risk factor associated with being female may be that employment is often combined 
with being responsible for the majority of housework and childcare at home, which may 
lead to increased stress, diminished rest, and increased susceptibility to ME/CFS (Jason 
et al., 1999).   
Age. ME/CFS appears to primarily affect adults, with reported point prevalence 
for adolescents being only 0.11% (Nijhof et al., 2011). However, research results have 
been mixed regarding associations between ME/CFS and particular adult age subsets. 
Some research has found that ME/CFS symptoms were reported at a significantly 
higher rate among individuals ages 40-69, with the greatest risk occurring between ages 
40-49 (Bierl et al., 2004; Jason et al., 1999). Other research has determined that the 
median age for onset for females was 31, while the median onset age for males was 33.5 
(Furberg et al., 2005). CDC (1997) surveillance results indicated that the mean age of 
onset was 34 years. A weighted point-prevalence study in Wichita, Kansas found that 
prevalence increased with age among white females, peaking between ages 50-59, and 
subsequently decreasing in ages 60 to 69 (Reyes et al., 2003). In a study involving 
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participants from the Swedish Twin Registry, no significant association was found 
between age and ME/CFS symptoms (Evengard et al., 2005).     
Education. Previous research has provided conflicting evidence pertaining to 
typical levels of education among ME/CFS participants. Some U.S. research found that 
ME/CFS symptoms were most likely among individuals who had only high school 
education or less (Bierl et al., 2004; Jason et al., 1999), while other research found that 
the majority of ME/CFS sufferers (63%) had attained education beyond high school 
(Nisenbaum et al., 2003). CDC (1997) surveillance results from four U.S. cities 
(Atlanta, Wichita, Grand Rapids, and Reno) found that the majority of individuals with 
the disorder had attended college (although not all had completed a degree). Research 
conducted via the Swedish Twin Registry, however, found no differences in educational 
attainment, when comparing fatigued and non-fatigued participants (Evengard et al., 
2005).  
Income. Results have been mixed regarding typical income attainment of 
individuals with ME/CFS. Some research has found that ME/CFS symptoms have the 
highest prevalence among individuals with annual incomes of $40,000 or less and that 
lower education and less income were the strongest predictor of symptoms (Bierl et al., 
2004). When compared to individuals from middle and high socioeconomic status 
(SES), individuals with chronic fatigue who are from lower SES scored significantly 
higher on measures of cognitive difficulties and of worsened fatigue following physical 
exertion (Jason et al., 2002). In the CDC (1997) surveillance study, individuals earning 
$20,000-$50,000 annually composed the largest group (45%) of patients.  Community-
based research in Wichita, Kansas, on the other hand, found that the highest rates of 
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ME/CFS were found in individuals earning greater than $40,000 per year (Nisenbaum 
et al., 2003).  
Cultural background. ME/CFS does not appear to be culture-bound. 
Multivariate analyses of epidemiological and clinical datasets from twenty-one 
countries having widely-varying cultures (including European and non-European, as 
well as English- and non-English-speaking) found that symptom profiles for ME/CFS 
remained consistent, regardless of culture (Hickie et al., 2009). When datasets from 
three English-speaking countries (the United States, the United Kingdom, and 
Australia) were utilized, the results were comparable to those found when using the 
entire dataset. Thus, the ME/CFS symptoms composite does not appear to be culturally- 
or medically-constructed. 
Symptom Domains 
In a meta-synthesis of 325 peer-reviewed qualitative studies of ME/CFS, the 
three symptoms most often reported by participants were severe fatigue, disabling pain, 
and cognitive difficulties (Anderson, Jason, Hlavaty, Porter, & Cudia, 2012). In 
contrast, a factor analysis of empirically-derived data from existing international 
datasets revealed that a five-factor model best explained ME/CFS (Hickie et al., 2009). 
The five domains were: (a) inflammation, (b) neurocognitive problems, (c) 
musculoskeletal pain and/or fatigue, (d) disturbed mood, and (e) disrupted sleep and/or 
fatigue. These factors were evident across cultures and throughout medical settings.  
Factor analysis of responses provided by individuals from Wichita, Kansas who 
had varying levels of ME/CFS symptom manifestations revealed that a three-factor 
model explained the symptom picture (Nisenbaum et al., 2004). The three factors 
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included musculoskeletal symptoms, infection symptoms, and cognitive-mood-sleep 
symptoms.  
A random sample of 18,675 individuals from Chicago, Illinois found that 780 
(4.2%) reported experiencing chronic fatigue, although severity of fatigue varied (Jason 
et al., 2002). Factor analysis of participants’ responses to questions regarding their 
fatigue revealed that four factors explained 38% of total variance, namely: (a) lack of 
energy (weakness, tiredness, and fatigue), (b) physical exertion resulting in worsened 
fatigue, (c) problematic cognitive functioning (difficulties with concentration, memory, 
and information-processing), and (d) whether fatigue was relieved by rest.  
In data obtained from the Swedish Twin Registry, the most-commonly reported 
ancillary symptoms were unrefreshing sleep (79.87%), impaired memory/concentration 
(48.48%), muscle pain (37.26%), and joint pain (37.26%; Sullivan, Pedersen, Jacks & 
Evengard, 2005). The four least-frequently reported ancillary symptoms were tender 
lymph nodes (6.89%), headaches of a new type (11.11%), sore throat (11.99%), and 
post-exertional malaise (15.76%).   
Finally, cluster analyses revealed that participants with ME/CFS fall into three 
differing subcategories of fatigue patterns, making the ME/CFS population a 
heterogeneous group (Jason et al., 2010). These subcategories are: low, moderate, and 
severe, with categorization based upon severity of postexertional fatigue, wired fatigue, 
brain fog, diminished energy, and flu-like fatigue. 
Course of Illness  
Review of existing literature revealed that the majority of patients with ME/CFS 
engaged in lifestyles that were active and healthy, prior to becoming ill (Carruthers & 
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van de Sande, 2005). During the year prior to ME/CFS onset, individuals typically 
evidenced elevated levels of stress (Masuda, Munemoto, Yamanaka, Takei, & Tei, 
2002). Individuals with ME/CFS have also often described experiencing the onset of 
illness as being comparable to a severe form of influenza, and patients have reported 
that, when the “flu” did not improve, they experienced emotional distress and believed 
they had lost their identity (Clarke & James, 2003). In qualitative research, individuals 
often reported that they were “catapulted from a period of excessive busyness to a 
period of complete immobility” (Clarke & James, 2003, p. 1390). 
Research focusing on illness onset has yielded mixed results. For example, 
Nisenbaum et al. (2003) found that 75% of participants described the onset of their 
illness as gradual. The CDC (1997) surveillance study also found that the majority of 
patients experienced gradual onset of their illness. On the other hand, in qualitative 
research with participants from Canadian support groups, onset was typically sudden 
(Clarke, 1999; Clarke & James, 2003). 
A meta-synthesis of qualitative studies found that individuals with ME/CFS 
tended to experience extensive variability in both symptom severity and frequency 
(Andersen et al., 2012). Significant levels of impairment were reported by the majority 
(60.54%) of symptomatic individuals in the Swedish Twin Registry (Sullivan et al., 
2005).  Individuals with ME/CFS who were tracked for up to three years were found to 
display an illness course characterized by intermittent periods of relapse and remission 
and by an overall decrease in symptoms over time (Nisenbaum et al., 2003).  
Research regarding the prognosis for ME/CFS symptom resolution has also 
yielded mixed results. CDC (1997) surveillance results found that the mean duration of 
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illness was slightly over six years. In a longitudinal study, at three-year follow-up, 20-
33% of participants continued to meet criteria for ME/CFS, 56.9% were in partial or 
total remission, 10% had sustained remission, and 23.1% had received substitute 
diagnoses (Nisenbaum et al., 2003). Higher total number of symptoms and increased 
fatigue severity scores were negatively related to achieving remission. Having had an 
illness duration of two years or less was a significant predictor of maintaining sustained 
remission. Systematic review of literature on the prognosis of ME/CFS found that few 
patients (6-15%) reported complete symptom resolution (Cairns & Hotopf, 2005; 
Pheley, Melby, Schenck, Mandel, & Peterson, 1999).  
Patients who developed ME/CFS following infection with an identifiable 
infectious agent (e.g., Epstein-Barr virus, cytomegalovirus, etc.) experienced a shorter 
illness duration than those who developed ME/CFS in the absence of an identifiable 
infection (Masuda et al., 2002). Individuals who developed ME/CFS following 
infection with Giardia duodenalis were found to resolve ME/CFS symptoms within 
three-to-five years (Morch et al., 2013). 
Diagnostic Challenges 
 Medical professionals have reported having an inadequate understanding of 
ME/CFS (Bayliss et al., 2014). One of the complexities of diagnosing ME/CFS lies in 
that distinctive laboratory tests are not yet available to identify the disorder, meaning 
that diagnosis is based upon symptoms, impaired functioning, and exclusion of other 
disorders that might explain symptoms (Reeves et al., 2003). For example, general 
practitioners in the United Kingdom were found to exclude the following disorders, 
prior to diagnosis: thyroid disorders (75%), anemia (73%), mood disorders (47%), 
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diabetes (38%), Epstein-Barr virus (19%), kidney disorders (17%), and liver disorders 
(10%; Bowen, Pheby, Charlett, & McNulty, 2005). Such exclusionary bases for 
diagnosis create difficulties in ascertaining the accuracy of diagnosis. 
Quest for Biomarkers. The current quest for an ME/CFS biomarker centers 
upon inflammatory models of the disorder (Arnett & Clark, 2012). A distinct challenge, 
however, is that many of the biomarkers of inflammatory processes that appear to be 
involved in ME/CFS are also found in other inflammatory disorders, making reliance on 
inflammatory biomarkers for diagnosis problematic. However, recent research by Light 
and colleagues (2011) has identified changes in the expression of seven specific genes 
that differentiated a large subgroup of ME/CFS patients from healthy controls with 
accuracy of .80. It has been suggested that lab tests of these gene expressions could be 
combined with behavioral assessments to increase the accuracy of ME/CFS diagnosis.   
Competing Diagnostic Models. An additional complexity of diagnosis is that 
various diagnostic criteria for ME/CFS exist, including: the CFS Research Case 
Definition (Fukuda et al., 1994), the Centers for Disease Control and Prevention 
Recommendations (Reeves et al., 2003), the Canadian Consensus Document 
(Carruthers & van de Sande, 2005), and the International Consensus Criteria 
(Carruthers et al., 2011). Anderson and colleagues (2012) noted that this lack of 
diagnostic consensus has led to tensions between the various players associated with 
ME/CFS, with qualitative research indicating that these tensions detrimentally impact 
patients. 
 
  
99 
 
Models of Diagnostic Criteria 
As noted previously, multiple diagnostic criteria for ME/CFS exist, and the lack 
of consensus on criteria has led to dissension within the field (Anderson et al, 2012). 
Among the diagnostic models mentioned above, the CFS Research Case Definition 
(Fukuda et al., 1994) diagnostic criteria persists as the most widely-utilized diagnostic 
criteria (Brown et al., 2013), but debate continues as to the appropriate criteria to be 
utilized in diagnosing ME/CFS.  
 CFS Research Case Definition. Fukuda et al. (1994) developed a set of 
diagnostic guidelines designed to distinguish CFS from neuropsychiatric disorders and 
from other fatiguing physiological conditions.  (Note: Fukuda et al. opposed changing 
the disorder’s name from CFS to an alternative label. Therefore, in discussing the views 
of Fukuda et al., this study will refer to the disorder as CFS.). Noting that psychiatric 
disorders, such as somatoform disorder, major depressive disorder, anxiety disorders, 
etc., were sometimes confounded with CFS, Fukuda et al. (1994) sought to establish 
clarity in diagnostic delineation. The primary motivation for establishing the Fukuda et 
al. (1994) criteria was to increase the validity of research on CFS. 
 The Fukuda et al. (1994) diagnostic criteria requires a minimum of six 
consecutive months of sustained or recurrent fatigue that is of new onset, does not stem 
from exertion, is not resolved by rest, and leads to significant reductions in previous 
activities. In addition, at least four of the following symptoms must have occurred 
concurrently throughout those six months: (a) diminished concentration or memory that 
impacts abilities to function in previous activities; (b) sore throat; (c) tender lymph 
nodes; (d) pain in muscles; (e) pain in multiple joints without redness or swelling; (f) 
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headaches that differ in severity, pattern, or types from previous experience; (g) sleep 
that is not refreshing; and (h) malaise lasting for at least twenty-four hours following 
exertion. Furthermore, in order to arrive at diagnosis, clinicians must have completed: 
(a) a comprehensive medical and psychosocial history, (b) a mental status examination, 
(c) a complete physical examination, and (d) a battery of relevant laboratory screenings. 
When all other sources of symptoms were excluded, a diagnosis of CFS might be made.   
Criticisms of the Fukuda et al. (1994) criteria have centered upon its polythetic 
approach, meaning that not all symptoms must be present for diagnosis (Jason et al., 
2012). Since four of eight symptoms are required for diagnosis, using the Fukuda et al. 
criteria, individuals may be diagnosed without evidencing symptoms that are considered 
core to CFS (e.g., post-exertional malaise; Brown et al., 2013).  
An additional concern with the Fukuda et al. (1994) criteria has to do with 
research  not justifying the cut-point requiring that four out of eight ancillary symptoms 
be present (Sullivan et al., 2005). By establishing a cut-point in number of symptoms, 
the Fukuda et al. (1994) criteria assumed that there were notable differences between 
patients reporting zero-to-three ancillary symptoms and those reporting four-to-eight 
(Sullivan et al., 2005). However, research utilizing data from the Swedish Twin 
Registry found that the diagnostic cut-point of four ancillary symptoms was not 
clinically-meaningful. Rather than demarcating between normalcy and pathology, no 
important differences existed between patients reporting three symptoms and those 
reporting four symptoms. 
Yet another critique of the polythetic approach utilized by the Fukuda et al. 
(1994) criteria surrounds the inherent supposition that “the ancillary symptoms are 
101 
 
fundamentally interchangeable and thus similar in their impact on the probability of 
CFS” (Sullivan et al., 2005, p. 1344). Data from the Swedish Twin Registry revealed 
that this assumption was not supported, as prevalence of symptoms reported ranged 
from ~7% for tender lymph nodes to ~80% for unrefreshing sleep. In fact, the eight 
ancillary symptoms were not equivalent in their individual ability to predict the 
disorder. 
As a result of research indicating that post-exertional malaise is a component of 
the CFS symptom picture, the Fukuda et al. (1994) criteria have also been critiqued for 
failing to include this symptom (Maes, Twisk, & Johnson, 2012). An additional 
criticism of the Fukuda et al. (1994) criteria is its requirement that fatigue be present for 
over six months (Brown et al., 2013).  
Centers for Disease Control and Prevention Recommendations. The Centers 
for Disease Control and Prevention (CDC) Recommendations arose out of concerns that 
the existing CFS Research Case Definition (i.e., Fukuda et al., 1994) contained 
ambiguities that led to inconsistencies in diagnosis (Reeves et al., 2003). Between May, 
2000 and May 2002, the CDC sponsored structured workshops with international 
ME/CFS experts from the fields of infectious disease, epidemiology, immunology, 
endocrinology, neurology, psychiatry, psychology, and biostatistics, as well as CDC 
staff and patient advocates. The purpose of the workshops was to evaluate the existing 
CFS Research Case Definition (i.e., Fukuda et al., 1994), to review existing scientific 
research literature, to discuss clinical experiences, and to brainstorm solutions to the 
existing diagnostic difficulties. From these sessions, summaries were compiled, 
analyzed, and drafted into formal recommendations. The final document resulted in a 
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series of recommended modifications to the CFS Research Case Definition presented by 
Fukuda and colleagues. 
 Among the CDC diagnostic modifications was the development of a specific list 
of exclusionary diagnoses, divided into three domains (Reeves et al., 2003). These 
categories were: (1) permanent medical exclusions (e.g., systemic lupus, Sjogren’s 
syndrome, multiple sclerosis); (2) temporary medical exclusions (e.g., untreated 
diabetes mellitus, sepsis, morbid obesity); (3) and permanent psychiatric exclusions 
(e.g., schizophrenia, bipolar disorder, organic brain disorders). The CDC criteria further 
clarified that short-term psychiatric conditions that had been resolved for over five years 
should not be considered in exclusionary diagnosis. CDC Recommendations included 
suggestions of standardized assessments that might be utilized in diagnosis (e.g., the 
CDC Symptom Checklist).    
 The CDC Recommendations also noted that the Fukuda et al. (1994) criteria 
required that fatigue associated with CFS not be related to continued exertion (Reeves 
et al., 2003). This stipulation presumably sought to distinguish ME/CFS from the 
normal levels of fatigue experienced by typical persons who engage in excessive 
activities. However, this Fukuda et al. (1994) requirement created diagnostic 
difficulties, in that individuals with ME/CFS often do experience extreme fatigue and 
malaise following activities that were previously tolerated well. Thus, the CDC 
Recommendations proposed that fatigue should be assessed in light of whether it 
stemmed from over-exertion that would fatigue a healthy adult.  
 CDC Recommendations also addressed the Fukuda et al. (1994) criterion that 
fatigue not be substantially relieved by rest (Reeves et al., 2003). CDC experts noted 
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that most individuals with ME/CFS do experience some relief from fatigue upon 
resting, although rest does not bring about the level of pre-illness physiological or 
cognitive stamina. It was also pointed out that incorporating rest periods into activities 
is often helpful to some patients with ME/CFS. Therefore, the CDC Recommendations 
proposed that rest as a therapeutic measure should not be used to exclude an individual 
from an ME/CFS diagnosis.  
Recent research has revealed problems with both the sensitivity and the 
specificity of the CDC criteria (Jason et al., 2010). In a study involving participants 
diagnosed with ME/CFS and participants diagnosed with Major Depressive Disorder 
(MDD), the CDC criteria failed to differentiate between ME/CFS and MDD (Jason, 
Najar, Porter, & Reh, 2008). In fact, 38% of the individuals previously diagnosed with 
MDD were inaccurately classified as having ME/CFS, when the CDC criteria were 
used.  
Jason and colleagues (2008) speculated that aspects of the CDC criteria that may 
have contributed to lack of specificity might include the CDC criteria requiring that 
symptoms be present for one month (as compared to the six months required by the 
Fukuda et al. [1994] criteria). This reduction in length of time that symptoms are 
present might allow some symptoms to be included as part of the ME/CFS diagnosis 
that were actually a part of a transient physical ailment such as influenza.  
Further, the CDC criteria do not differentiate between symptoms critical to 
ME/CFS diagnosis, such as sleep disturbance, cognitive difficulties, and postexertional 
malaise, and other less-definitional symptoms (Jason et al., 2008; Jason et al., 2012). 
Since all symptoms are given equal value in the CDC criteria, “a participant reporting 
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severe and frequent headaches is given the same value as a participant reporting severe 
and frequent postexertional malaise” (Jason et al., 2008, p. 6). The CDC criteria has 
also been criticized as targeting broad areas, such as social functioning, difficulties 
fulfilling roles, and activity issues (Jason et al., 2012).  
The Canadian Consensus Document. The Canadian Consensus Document 
arose from the efforts of the National Myalgic Encephalomyelitis/Fibromyalgia Action 
Network of Canada to develop expert consensus on the diagnostic criteria for ME/CFS 
(Carruthers & van de Sande, 2005). A questionnaire was sent to physicians across 
Canada, requesting input regarding what they believed to be most helpful in diagnosing 
ME/CFS patients. Using these responses, a panel of ten ME/CFS experts drafted an 
illness definition and diagnostic criteria.    
 The Canadian Consensus Document defined ME/CFS as “an acquired organic, 
pathophysiological, multi-systemic illness that occurs in both sporadic and epidemic 
forms” (Carruthers & van de Sande, 2005, p. 1). Diagnostic criteria included:  
1) Fatigue - Significant physical and mental fatigue that is unexplained, 
chronic, and notably reduces activity. 
2)  Post-Exertional Malaise and/or Fatigue – Excessive reduction in physical or 
mental stamina; rapid onset of fatigue; and/or, post-exertional malaise, 
fatigue and/or pain. 
3) Sleep Dysfunction – Sleep disturbance or unrefreshing sleep. 
4) Pain – Significant myalgia that may be experienced in muscles and joints 
and that may migrate and/or headaches “of new type, pattern or severity” (p. 
2). 
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5) Neurological/Cognitive Manifestations – Two or more of the following 
symptoms are present: poor concentration and short-term memory; 
confusion; disorientation; impaired information processing, retrieval of 
words, and categorization; disturbances of perception and sensory 
experiences; and/or, cognitive, sensory, and/or emotional overload. 
6) At least one symptom from two of the following:  
a. Autonomic Symptoms – Orthostatic intolerance, lightheadedness, 
significant pallor, palpitations, neurally-mediated hypotension, 
postural orthostatic tachycardia syndrome, and/or exertional dyspnea. 
b. Neuroendocrine Symptoms – Repeated episodes of feeling feverish, 
marked weight change, and/or increased symptom severity associated 
with stress. 
c. Immune Symptoms – Repeated flu-like symptoms, general malaise, 
lymph node tenderness, repeated sore throat, and/or new sensitivity 
to medications, foods, and/or chemicals. 
7) In an adult, the illness continues for six or more months (more than three 
months, if diagnosing a child). 
In addition, the Canadian Consensus Document (Carruthers & van de Sande, 2005) 
requires that (a) symptoms must have begun or become more pronounced after the onset 
of the disorder, (b) clusters of symptoms may fluctuate and vary over time, and (c) 
active disorders that might explain the majority of symptoms should be excluded, prior 
to diagnosis with ME/CFS. 
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When the CDC criteria were compared to the Canadian Consensus criteria; 
however, the CDC criteria was not as sensitive in discriminating between those with 
ME/CFS and those without the disorder (Jason et al., 2012). Symptoms typically 
considered cardinal traits of ME/CFS, including postexertional malaise and 
neurocognitive difficulties, did not predict diagnosis in the CDC criteria, but they did 
predict diagnosis using the Canadian criteria. 
 International Consensus Criteria. The International Consensus Criteria arose 
out of significant modifications to the Canadian Consensus Criteria (Carruthers & van 
de Sande, 2005; Carruthers et al., 2011). In developing the International Consensus 
Criteria, a panel of researchers, clinicians, educators, and an unaffiliated patient 
advocate collaborated in drafting, reviewing, and revising the diagnostic criteria. The 
panel was free of sponsorship and consisted of experts from thirteen countries and from 
a range of specializations.  
 The International Consensus Panel was motivated by a desire to develop a set of 
diagnostic criteria that would better assist in differentiating ME/CFS from other 
illnesses (Carruthers et al., 2011). In particular, there were concerns that the Fukuda 
(1994) criteria failed to differentiate ME/CFS from depressive disorders. Additionally, 
the CDC Criteria were believed to be too broad and inclusive to adequately identify 
patients with ME/CFS. Further, the panel wished to improve upon the Canadian 
Consensus Criteria. To that end, the International Consensus Criteria focused on the 
following changes:  (a) reducing the six-month waiting period for diagnosis, (b) 
replacing the term fatigue with postexertional neuroimmune exhaustion, and (c) better 
clarifying and operationalizing symptoms (Carruthers et al., 2011).  
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Thus, according to the International Consensus Criteria, an individual must meet 
the following criteria to be diagnosed with ME/CFS: (a) symptoms of postexertional 
neuroimmune exhaustion; (b) one or more symptom of neurological impairment; (c) 
one or more symptom of either immune, gastro-intestinal, or genitourinary difficulty; 
and (d) one or more symptom of impaired energy metabolism or energy transport 
(Carruthers et al., 2011). Furthermore, to be diagnosed with ME/CFS, symptoms must 
be so severe that the individual’s premorbid activity level is significantly reduced. 
Postexertional neuroimmune exhaustion was described by the International 
Consensus Criteria as a “cardinal feature” of the disorder and was defined as “a 
pathological inability to produce sufficient energy on demand with prominent 
symptoms primarily in the neuroimmune region” (Carruthers et al., 2011, p. 329). 
Manifestations of postexertional neuroimmune exhaustion included: (a) profound and 
rapid physical and/or cognitive fatigue following exertion (including minimal levels of 
exertion associated with daily tasks); (b) postexertional exacerbation of symptoms (e.g., 
malaise, pain, intensification of other symptoms); (c) postexertional exhaustion; (d) 
prolonged recovery period (i.e., typically greater than 24 hours); and (e) substantial 
reduction in physical and mental stamina that leads to marked reduction of premorbid 
activity.   
Neurological impairments were divided into four categories: (a) neurocognitive 
impairments (i.e., impaired information processing and/or loss of short-term memory); 
(b) experience of pain (headaches and/or noninflammatory pain); (c) disturbances to 
sleep (i.e., disrupted sleep patterns and/or unrefreshing sleep); and (d) neurosensory, 
perceptual, and motor disturbances (e.g., impaired visual focus, hypersensitivity to 
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sensory stimuli, disturbed depth perception, difficulties with coordination; Carruthers et 
al., 2011).  
Immune, gastro-intestinal, and genitourinary impairments consisted of five 
categories: (a) recurrent or chronic flu-like symptoms that usually activate or become 
worse with exertion; (b) increased susceptibility to viral illnesses with lengthy recovery; 
(c) gastro-intestinal tract symptoms (e.g., irritable bowel syndrome, nausea, abdominal 
discomfort); (d) genitourinary symptoms (e.g., increased urinary frequency or urgency); 
and (e) sensitivity to chemicals, medications, foods, or smells (Carruthers et al., 2011). 
Impairment of energy production/transport included at least one of the following 
symptoms: (a) cardiovascular (e.g., orthostatic intolerance, palpitations, light-
headedness, dizziness); (b) respiratory (e.g., labored breathing, shortness of breath); (c) 
loss of thermostatic stability (e.g., recurrent sensations of feverishness, episodes of 
sweating); and (d) intolerance of temperature extremes (Carruthers et al., 2011). 
The International Consensus Criteria also clarified levels of impairment, ranging 
from mild to very severe, noting that symptom severity might fluctuate (Carruthers et 
al., 2011). Additionally, the criteria provided increased clarification for pediatric 
diagnosis. Furthermore, the diagnostic criteria allowed for an alternative diagnosis of 
atypical myalgic encephalomyelitis for individuals who experience postexertional 
neuroimmune exhaustion, but exhibit two fewer symptoms than is required for full 
diagnosis of ME/CFS. 
Research comparing the International Consensus Criteria (Carruthers et al., 
2011) with the Fukuda et al. (1994) criteria found that individuals who met the 
International Consensus Criteria exhibited more pronounced impairment in their 
109 
 
functional abilities and greater numbers of physical, cognitive, and mental difficulties 
than those diagnosed using the Fukuda et al. criteria (Brown et al., 2013). Further, the 
Fukuda et al. criteria resulted in a much larger number of diagnoses than the 
International Consensus Criteria, indicating increased specificity in the International 
Consensus Criteria. 
 Finally, Maes, Twisk, and Johnson (2012) expressed that the International 
Consensus Criteria should be modified to include ME as a subset of CFS. This assertion 
was based upon research revealing that 45.8% of participants with ME/CFS (according 
to Fukuda et al. [1994] criteria) could be differentiated by their experience of 
postexertional malaise and by clinical indications of increased inflammatory/infectious 
processes.   
Difficulties with Obtaining a Diagnosis 
Individuals with ME/CFS have often reported that obtaining a diagnosis was an 
arduous process (Clarke & James, 2003; Cooper, 1997; Ware, 1992). Patients 
frequently endeavored to find a physician who could recognize, explain, and treat their 
symptoms (Clark & James, 2003), and they often saw multiple physicians in their quest 
for a diagnosis (Clarke, 1999; Cooper, 1997). Patients were found to have visited 
between three and four hospitals, complaining of their symptoms, prior to receiving 
diagnosis (Masuda et al., 2002). Despite medical examinations, the absence of organic 
abnormalities often led to lack of diagnosis. Patients frequently went undiagnosed for 
several years (Cooper, 1997), and many symptomatic individuals were never able to 
obtain a medical diagnosis (Clark & James, 2003). Individuals often described the 
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difficulties in obtaining diagnoses from their doctors as reducing them to “rock bottom” 
and as leading them to pessimism over the future (Cooper, 1997, p. 196).  
The likelihood of being formally diagnosed with ME/CFS appears to be based 
upon individual dynamics, such as access to medical care, willingness to pursue a 
protracted and vigorous quest for services, determination to obtain a diagnosis, and the 
attitudes of the treating physicians (Huibers & Wessely, 2006). Even when finally 
diagnosed, however, many individuals reported that their physicians expressed some 
doubt about whether ME/CFS was a legitimate disorder (Cooper, 1997). 
“It must be in your head." Both health professionals and laypersons tend to 
view illnesses in a dualistic manner, namely that the source of the disorder is either 
physiological or psychological (Chalder, 2005). Substantial research suggests that when 
medical explanations are not readily available, medical professionals may default to 
psychological explanations (e.g., Nettleton, 2006). Given the current lack of a fully 
understood medical model of ME/CFS, and given the current absence of biomarker 
assays, ME/CFS patients are sometimes diagnosed with a psychological explanation for 
their symptoms (Anderson et al., 2012).  
Providing a psychological explanation for illness often implies that the patient is 
somehow to blame for their difficulties, while providing a physical explanation for 
difficulties typically does not (Nettleton, O’Malley, Watt, & Duffey, 2004). 
Furthermore, within the modern realm of biomedicine, psychological explanations are 
typically devalued as less “legitimate” than those that are organically explained (p. 47). 
In a meta-synthesis of qualitative studies, a salient theme among the accounts of those 
exhibiting ME/CFS symptoms was that of experiencing stigmatization by family, 
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friends, and medical professionals in association with having their illness experience 
labeled as psychosomatic (Anderson et al., 2012).  
Qualitative research has revealed that, for some patients who lack a medical 
explanation for their symptoms, pragmatic difficulties arise from attributing their 
symptoms to psychological sources (Nettleton et al., 2004). Namely, patients have 
reported that medical professionals and family members no longer proffered support, as 
they believed symptoms were “explained away” (p. 55). Furthermore, the psychological 
attributions posed difficulties in engaging additional professionals to procure a medical 
diagnosis, as the psychological explanation became a part of the medical record that 
followed the patient “like a criminal record” (p. 55). The combination of these 
challenges made it increasingly difficult for the ill person to seek help. 
 Dimsdale (2011) pointed out several concerns about applying psychiatric 
diagnoses to symptom composites that are not yet fully understood or explained by the 
medical profession.  First, the quality of medical evaluations should be considered, as 
doctors vary in their individual knowledge repertoires, in the thoroughness of their 
examinations, in the amount of time they spend on each patient’s case, and in their 
ability to synthesize information. Additionally, the current state of medical knowledge 
may have not yet identified the etiology, underlying processes, or existence of a 
disorder.  
Dimsdale (2011) described this concern as follows: 
…diagnoses are shaped by the state of medical knowledge at the time when the 
patient is evaluated. One ‘sees’ what one is prepared to see or understand. If one 
has no tools for recognizing hepatitis C, for instance, one will not make that 
diagnosis until very late in the progression of the infection. New diseases are 
constantly arising, either totally new diseases or, more commonly, disease that 
have previously not been well understood. (p. 511)  
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An additional consideration posed by Dimsdale (2011) is that many illnesses present 
with nonspecific symptoms that are difficult to diagnose until medical technologies, 
such as bioinstrumentation and assay development, progress to the point of allowing for 
detection.    
 In similar fashion, Anderson and colleagues (2012) argued that attributing 
ME/CFS symptoms to psychosomatic sources is a form of victim blaming, in which 
patients may be blamed for the lack of inadequate scientific knowledge of ME/CFS. 
Horton-Salway (2002) described it as the construction of “a narrative associated with 
low accountability for doctors and high accountability for patients” (p. 416). Given that 
women are more likely to suffer from ME/CFS (Bierl et al., 2004; Furberg et al., 2005; 
Jason et al., 2009), Richman and Jason (2001) argued that the failures of the medical 
community to identify biological markers for ME/CFS has been used to reinforce social 
ideas that link female gender to psychiatric explanations of illness.  
Furthermore, qualitative research has revealed that the psychological 
explanation for unexplained illness symptoms was found to contribute to social 
isolation. Nettleton and colleagues (2004) described this social dilemma, as follows: 
She is in a double bind; if she reveals that she feels ‘down’ or ‘depressed’ this 
would only reinforce those psychological interpretations. She has therefore to 
work hard at her presentation of self. To get angry, anxious, depressed, unhappy, 
or suicidal would serve to confirm an identity that she has to work hard to 
dispel. (p. 56) 
 
The significance of diagnosis to patients. The importance of diagnosis of 
ME/CFS for patients lies, in part, in the need for health-related shifts in roles and 
behaviors, as a result of illness symptoms. As Chrisman (1977) noted, “Illness-related 
shifts in role behavior imply a ‘bargaining’ process in which modified rights and 
113 
 
obligations are established with others in the social environment” (p. 357). The lack of 
visible symptoms in ME/CFS creates increased difficulties for patients who are 
attempting to achieve modifications to their previous roles. Chrisman explained,  
Unambiguous acute symptoms place the individual in the strongest position for 
attaining the fullest extent of modifications in role behaviors and place upon him 
the strongest obligations to get well. On the other hand, ambiguous or chronic 
problems are not nearly so compelling. (p. 357)  
 
Given the ambiguous and chronic nature of ME/CFS, the need to obtain a 
diagnosis is particularly pronounced among patients who are attempting to bargain for 
adjustments in work, familial, or social roles. According to Clarke and James (2003), 
when ill individuals obtain a diagnosis, they are granted a “transitional identity as a 
person whose body is temporarily in poor functioning order, a person in a ‘special’ 
medically legitimated place in the social order” (p. 1393). When these individuals are 
not medically or socially permitted to take on the sick role, they “[lack] a place in the 
social order and [have] no obvious way of returning to his/her previous place” (p. 
1393). Further,  
The lack of a clear and generally accepted diagnosis in the case of CFS means 
that the self is without the legitimating discourse from the powerful medical 
profession. Because most people have lost jobs and friends, they also lack the 
legitimacy offered by a place in the economic and social structural orders. 
(Clarke & James, 2003, p. 1393) 
 
Qualitative research with ME/CFS sufferers has produced similar outcomes, with 
patients reporting experiencing difficulties with both employers and with family in 
association with lack of diagnosis. Cooper (1997) described these difficulties as 
follows: 
By not being allowed full and decisive entry into the sick role, sufferers found 
that their social position was eroded, their social identity devalued and 
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stigmatized, whilst they found it difficult to obtain legitimate absence from work 
or disability benefit. (p. 196). 
Not surprisingly, the quest for a diagnosis was often linked by patients to a need 
to have their suffering named, to find potential relief from symptoms, to generate 
meaning out of the confusing constellation of symptoms, to experience validation of 
their sickness, and to attain the sick role (Cooper, 1997). In their qualitative research 
with individuals who struggled to find a diagnosis and explanation for the symptoms, 
Nettleton and colleagues (2004) noted that an additional concern is that these patients 
experience difficulties in making “sense” of or reconstructing “explanatory models” of 
their symptoms, since they cannot yet connect their illness to medical theory (p. 47). In 
light of this, these undiagnosed patients “hover precariously in a void between illness 
and disease” (p. 47), facing the specter of “no diagnosis, no prognosis” (p. 52).  
Additionally, lack of diagnosis means that one does not have a “categorical 
identity,” limiting the patient from joining group membership with others who share the 
illness or from seeking the support of others who face the same situation (Nettleton et 
al., 2004). Thus, lack of diagnosis leads to difficulties in obtaining both formal and 
informal sources of assistance and support. 
Interestingly, participants often reported having self-diagnosed, following 
discussion in support groups and self-assessment of symptoms (Clarke, 1999; Clark & 
James, 2003) or after discovering articles in periodicals that explained ME/CFS 
(Cooper, 1997). These approaches to self-diagnosis are in keeping with Chrisman’s 
(1977) Health-Seeking Process Model, a medical anthropological model that describes 
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how patients often consult with others in seeking to identify an illness, for suggestions 
in treatment, and for processing health professionals’ responses to their illness. 
 For those who were able to obtain a formal medical diagnosis, the process often 
involved locating a physician who was known to consider ME/CFS to be legitimate or 
one who was open to learning from patients about ME/CFS (Clark & James, 2003). 
Physicians who provided a diagnosis and support became sources of hope to patients 
(Cooper, 1997). Whereas not having a diagnosis had contributed to uncertainty and 
confusion, when patients finally obtained a label for the symptoms and an idea of the 
course of illness, they reported experiencing an increase in feelings of hopefulness 
(Fisher & Crawley, 2012). 
As might be predicted, obtaining diagnosis was often viewed as a symbolic 
milestone, and many reported psychosocial improvements as a result of identification of 
their illness (Cooper, 1997). Many experienced diagnosis as having “finally found some 
respite from the chaos and anarchy of their illness” (p. 196). 
Concerns of medical professionals regarding diagnosis. Huibers and Wessely 
(2006) described ME/CFS as “a cultural phenomenon and metaphor of our times” (p. 
897) that has been promoted by support groups, online information, self-help sources, 
and the media. The authors proposed that diagnosing the physical symptoms of 
ME/CFS as a legitimate illness may reinforce illness behaviors in patients, may result in 
self-validation and self-fulfilling prophesies, may contribute to negative outcomes, may 
lead to “transgression into the sick role,” and may lead to “development of an illness 
identity and the experience of victimization” (p. 898).  
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Posing the question, “…should we tell [a patient they have ME/CFS] or not?” 
Huibers and Wessley (2006) recommended that individuals who are in the acute or 
early stages of ME/CFS should not be informed of their diagnosis “because the label 
may stimulate chronicity” (p. 899). They proposed that physicians should only share the 
news of diagnosis with individuals who have suffered with ME/CFS for an extended 
period of time, who are in an advanced stage of illness, and who evidence only low 
chances of recovery. The rationale for providing a diagnosis to those with advanced 
ME/CFS was that receiving a diagnosis may provide “relief, acceptance and the 
preservation of self-esteem to the experience of illness” (p. 899).  
Interestingly, Huibers and Wessley (2006) did acknowledge that their advice to 
physicians regarding diagnosis was not without problems. In fact, their recommendation 
to provide symptomatic individuals a diagnosis, only after they had reached an 
advanced and prolonged state of illness, would, no doubt, be particularly difficult for 
individuals seeking validation of their symptoms. As Huibers and Wessley (2006) noted 
of ME/CFS sufferers:  
…the contrast between normal appearance and far from normal feeling, and the 
lack of objective or medically accepted disease verification, continues to leave 
the sufferer stranded uncomfortably between illness and disease. (p. 899) 
 Qualitative research with Swedish physicians noted that they, too, refrained 
from providing diagnoses to ME/CFS patients during the early stages of their illness, as 
a strategy “for hindering the patient from becoming too focused on his/her diagnosis 
and problems” (Asbring & Narvanen, 2003, p. 717). Furthermore, these medical doctors 
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reported that they did not provide their ME/CFS patients with medical papers necessary 
for exemption from work, during the early stages of illness, for the same reason.  
Illness Invalidation 
Illness invalidation has been defined as “a constellation of features that includes 
nonacceptance by others, misunderstanding, disbelief, rejection, stigmatization, and 
suspicion that the [health] problem is exaggerated or psychological” (Kool, 
Middendorp, Boeije, & Geenen, 2009, p. 1650). Illness invalidation may be particularly 
likely to occur when symptoms are invisible, ambiguous, and chronic.  
Individuals with chronic ambiguous conditions, including ME/CFS, have 
reported that their families and their medical professionals discounted their symptoms 
and doubted their experiences (Dickson et al., 2007; Johnson & Johnson, 2006). Illness 
invalidation has also been reported by patients with other “invisible” conditions, such as 
fibromyalgia (Kool et al., 2009), rheumatic diseases (Kool & Geenen, 2012) and 
chronic pain (Newton, Soutball, Raphael, Ashford, & LeMarchand, 2013). Moreover, 
individuals with ME/CFS reported belief that absence of visibly-apparent symptoms 
contributed to illness invalidation (Asbring & Narvanen, 2001; Dickson et al., 2007). 
Perspectives of medical professionals. As Clarke and James (2003) noted, 
“…one of the distinguishing features of CFS is that its reality is disputed by the medical 
profession” (p. 1393). Research involving general practitioners from the United 
Kingdom revealed that 28% did not believe that ME/CFS was an identifiable clinical 
diagnosis (Bowen et al., 2005). In the United States, 20% of physicians indicated belief 
that ME/CFS is “only in the patient’s head” (Brimmer, Fridinger, Lin, & Reeves, 2010, 
p. 8). In a meta-synthesis of 325 peer-reviewed qualitative studies, physician-specific 
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themes included skepticism that ME/CFS is a legitimate disorder and minimization of 
the ME/CFS illness experience (Anderson et al., 2012). Similarly, a meta-synthesis of 
studies spanning from 1988 to 2013 also echoed the finding that many medical 
professionals do not believe that ME/CFS is a real disorder, due to the limitations in 
pathological findings (Bayliss et al., 2014), current lack of objective tests to ascertain 
the disorder’s presence, and the lack of clearly-identified etiological mechanisms 
(Asbring & Narvanen, 2003). 
Medical doctors have been found to stereotype patients with ME/CFS, based on 
inadequate knowledge of the ME/CFS pathophysiology (Anderson et al., 2012). 
Physicians expressed perceptions of many ME/CFS patients as “illness focused, 
demanding, and medicalising” (Asbring & Narvanen, 2003, p. 711). In particular, 
physicians noted that individuals with ME/CFS do not act and appear the way someone 
who is ill “is expected to look and behave,” and they indicated that their assessment of 
physical appearance weighed heavily in their interpretation of the legitimacy of a 
patient’s symptom description (Asbring & Narvanen, 2003, p. 714). In other words, 
physicians often doubted whether ME/CFS patients were legitimately ill or were 
attempting to obtain the sick role, procure time off from work, etc. (Asbring & 
Narvanen, 2003). Medical doctors made judgments about the veracity of their ME/CFS 
patients’ reports and often questioned the morality of the patient, especially of the 
individual’s work ethic. Similar research conducted with Swedish physicians who 
treated ME/CFS patients also reported physician skepticism about patient experiences, 
noting belief that the symptoms of ME/CFS were minor, that patients were exaggerating 
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the severity of their illness experiences, and that these patients had particularly 
pessimistic attitudes about life (Asbring & Narvanen, 2003).  
Physicians also frequently expressed the opinion that “it was not desirable to 
have too many of these patients, as it could prove difficult to put up with them 
psychologically” (Asbring & Narvanen, 2003, p. 715). Medical doctors, particularly 
males, reported consciously avoiding and distancing themselves from their ME/CFS 
patients. In research involving general practitioners in the United Kingdom, only 12% 
indicated that they enjoyed seeing patients with ME/CFS (Bowen et al., 2005). Those 
who accepted the legitimacy of ME/CFS were over twice as positive about working 
with these patients. 
Interestingly, many of the stereotypically negative behaviors of ME/CFS 
patients might be considered a normal part of the health-seeking process when viewed 
through the lens of medical anthropology. Based upon anthropological studies of health-
related behaviors in the U.S., Chrisman (1977) developed the Health Seeking Process 
Model, in which the stages of illness typically consist of gaining a definition of 
symptoms, obtaining shifts in roles to accommodate the illness, lay consultation and 
referral, treatment behaviors, and adherence. Because individuals with ME/CFS often 
experience difficulties obtaining diagnoses (Clarke & James, 2003; Masuda et al., 
2002), it would seem likely that these patients might become more persistent with their 
doctors, as diagnosis is often the first step in receiving cultural permission to shift work, 
familial, and social roles to accommodate the illness (Chrisman, 1977).   
Research has also suggested that doctors treating ME/CFS patients often did not 
share patients’ understanding of terms used to describe symptoms (Cooper, 1997). 
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Cooper (1997) described this as a “breakdown of a shared meaning system, where the 
same term signifies different experiences” (p. 197). For example, patients who used the 
term fatigue often later explained a different meaning for the term than is commonly 
understood. 
To sufferers, ‘fatigue’ means being so tired they cannot brush their hair or even 
sit up in bed. To doctors ‘fatigue’ may simply mean a term to describe a 
common occurrence in the general population as a result of modern-day stress. 
(Cooper, 1997, p. 197) 
As such, symptoms that were experienced as severe by the patients were trivialized by 
their physicians.  
In a more recent study, patients indicated that the impact of ME/CFS symptoms 
was significant, and yet, review of their medical records found that symptoms of fatigue 
were rarely included in medical documentation (Evengard et al., 2005). These results 
provide convergent support for the discrepant perspectives of symptoms by patients and 
their physicians.  
In a meta-synthesis of qualitative studies, the theme of obtaining diagnosis was 
found to intersect with the theme of patient-physician power dynamics (Anderson et al., 
2012). Physicians reported perceptions of individuals with ME/CFS as being doubtful 
of the doctor’s knowledge of ME/CFS and of the doctor’s likelihood of assisting them 
(Asbring & Narvanen, 2003). On the other hand, physicians often reported questioning 
their own professional knowledge as they worked with ME/CFS patients, and many 
expressed beliefs that there had been gaps in their medical education (Asbring & 
Narvanen, 2003). In another study, less than 30% of physicians reported having enough 
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information about making an ME/CFS diagnosis (Brimmer et al., 2010). Furthermore, 
doctors noted experiencing difficulties associated with being unable to provide causal 
explanations to patients, with having limited treatment options to offer, and with having 
inadequate answers to patients’ questions (Asbring & Narvanen, 2003; Brimmer et al., 
2010). Feelings of incompetence and helplessness, combined with patient 
dissatisfaction, appeared to threaten professional identity and contributed to physicians’ 
experiencing negative opinions of treating patients with ME/CFS (Asbring & Narvanen, 
2003).  
Additionally, a study involving 811 general practitioners in the United Kingdom 
found that 48% lacked confidence in diagnosing ME/CFS, and 41% lacked confidence 
in treating these patients (Bowen et al., 2005). Physicians who accepted the legitimacy 
of ME/CFS were roughly three times more confident about their ability to diagnose the 
disorder. Finally, other factors significantly associated with medical professionals 
endorsing the legitimacy of ME/CFS were: (a) having a personal acquaintance with 
ME/CFS, (b) being male, and (c) having treated a greater number of ME/CFS patients 
within the previous year. Physicians who had previously given an ME/CFS diagnosis 
were less likely to believe that the disorder was “in a patient’s head” (Brimmer et al., 
2010, p. 8).  
Perspectives of patients. Patients with ME/CFS have reported having their 
symptoms met with skepticism, disbelief, trivialization, and dismissal by medical 
professionals (Cooper, 1997; Deale & Wessely, 2001; Gilje, Soderlund, & Malterud, 
2008). In qualitative research, most ME/CFS patients reported finding their interactions 
with doctors to be more frustrating than helpful (Clarke, 1999). Individuals with 
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ME/CFS reported experiencing their physicians as doubting the legitimacy of their 
illness, disbelieving that the symptoms stemmed from organic causes (Clarke & James, 
2003), and generally misunderstanding the nature of their sickness (Cooper, 1997). In 
one study, over half of participants with ME/CFS (N = 211) reported belief that medical 
specialists did not seriously consider their complaints (53%) and did not sympathize 
with their illness experiences (54%; Prins et al., 2000). Further, ME/CFS patients have 
reported “being treated with disdain” and as “an annoying irritation” by their physicians 
(Arroll & Senior, 2008, pp. 453-454).  
Other patients reported that doctors misrepresented their symptoms as stemming 
from depression, rather than understanding that their depression was a consequence of 
living with a severe physiological illness (Cooper, 1997). Female patients, in particular, 
reported having their symptoms dismissed and doubted by their physicians, as well as 
being labeled as “malingerers” and “bored housewives” (p. 198). 
One participant reported: 
I had got a list of symptoms …one written down was mild depression. Having to 
give up work and be ill at the same time was bound to cause a slight 
depression…. Of course having the depression written down on a piece of paper 
he said, ‘Oh you women, that’s all you ever say…you’re depressed.’ ‘Bored 
Housewife Syndrome’ that’s what he called it. (Cooper, 1997, p. 198) 
 
Patients from this study also reported perceiving the lack of positive support 
from their doctors as reducing them to “rock bottom” and to a “bleak” outlook (Cooper, 
1997, p. 196). This type of interaction has been referred to as “psychogenic dismissal,” 
a term used to describe an experience wherein a patient experiences iatrogenic 
psychological harm as a result of having their symptoms dismissed as being “all in the 
mind” (p. 202). In addition, patients indicated that, in their struggle to obtain a 
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legitimate diagnosis, they often felt a great deal of pressure to demonstrate that they 
were genuinely ill and to appear to be “good” or “normal” patients (Cooper, 1997, p. 
199). They noted experiencing the need to prove that, although their illness might be 
considered “deviant,” they were not deviant themselves (Cooper, 1997, p. 199).  
Some ME/CFS patients have reported that their physicians appeared to resent 
their active involvement in the diagnostic process and seemed to perceive the 
involvement as a threat to their medical knowledge and their position (Cooper, 1997). 
Other patients expressed that, in trying to demonstrate that they were “good” patients, 
they did not “provoke” their doctors by sharing information they had learned about 
ME/CFS from other sources (p. 199). These patterns are in keeping with other 
qualitative research involving patients with unexplained medical illnesses who reported 
that they worried that, if they were not perceived as “working” to get well, they would 
be suspected of malingering (Nettleton, 2006). These same patients also reported 
withholding information about their symptoms, when interacting with medical 
professionals who were perceived as invalidating.  
Furthermore, the difficulties in obtaining a diagnosis often challenged patients’ 
“underlying myth” that physicians are symbols of authority and symbols of healing 
(Cooper, 1997). As doctors disappointed patients by failing to address their health 
needs, patients often felt frustration and contempt. These patients described reaching a 
point where they rejected their internalized myth of the doctor as healer and authority 
figure and came to trust more deeply in their own ability to gather information about 
their illness. Despite this “demystification” of physicians’ authority and increase in trust 
of self, these patients usually either confronted their existing doctor or changed medical 
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providers until a trusted physician could be found (p. 203). In qualitative research with 
patients who had unexplained illness, most understood that medical answers are not 
always straightforward and forthright; however, what these patients longed for was to 
have their medical professionals validate their illness experiences as “genuine” 
(Nettleton, 2006, p. 1170).  
Impact of illness invalidation from medical professionals. In Western culture, 
medical professionals are culturally-sanctioned as having power to officially recognize 
an individual’s symptoms as medically- and socially-legitimate (Cooper, 1997; 
Foucault, 1975; Hyden & Sachs, 1998; Woodward, Broom, & Legge, 1995). Foucault 
(1975) considered this power to be a form of medical policing, and others have 
interpreted it as “medical paternalism” (Finerman & Bennett, 1995, p. 2; Kirmayer, 
1988). Within such a culture, some patients are not granted a medical sanction for their 
illness, particularly those individuals whose symptoms are difficult to diagnose or who 
suffer from ambiguous or chronic health conditions (Chrisman, 1977; Waxler, 1980). 
Without this medical sanction, illness invalidation from medical professionals may have 
a pronounced negative impact on patients.  
Patients with ME/CFS have reported feeling confused, disempowered, self-
doubting, and vulnerable, as well as experiencing loss of identity, upon perceiving 
illness invalidation from medical professionals (Arroll & Senior, 2008; Woodward et 
al., 1995). Moreover, illness invalidation from medical professionals has been reported 
as contributing to lack of validation from family and employers (Cooper, 1997) and as 
potentially undermining social support that would typically accompany the sick role 
(Deale & Wessely, 2001). Furthermore, having medical professionals fail to validate 
125 
 
symptoms has reportedly contributed to individuals with medically-unexplained illness 
questioning themselves, even when they knew their symptoms to be real (Nettleton, 
2006). 
Illness invalidation from social networks. In qualitative research, individuals 
with ME/CFS reported experiencing emotional pain as a result of illness invalidation 
from significant others, family members, friends, and the work environment (Asbring & 
Narvanen, 2002; Dickson et al., 2007; Larun & Malterud, 2007). In a meta-synthesis of 
325 peer-reviewed qualitative studies of ME/CFS, a common theme among patients was 
the experience of reduced social connections and disrupted personal relationships in 
association with the illness (Anderson et al., 2012).  
Patients often reported that friends were skeptical of the legitimacy of their 
sickness, that they were judged and rejected by many in their previous social networks, 
and that they often lost their friendship networks (Clarke & James, 2003). Adolescent 
patients reported that some friends and teachers invalidated their experiences of fatigue, 
doubting them, appearing to distrust their reported symptoms, dismissing their illness as 
malingering, and attributing their physical inabilities to laziness (Fisher & Crawley, 
2012). Further, adolescents with ME/CFS noted having difficult experiences of teasing 
and bullying about their illness from peers. Other ME/CFS patients often reported 
feeling socially isolated and as though they were “outsiders” (Clark & James, 2003, p. 
1390). Further, patients often found it difficult to meet new friends, due to physical 
limitations on activities. 
Despite having a diagnostic label to explain their symptoms, ME/CFS patients 
reported that the lack of visible symptoms contributed to continued illness invalidation 
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from social networks (Fisher & Crawley, 2012). Patients reported having their 
symptoms trivialized and having others explain to them that “tiredness” is a normal 
experience (p. 564). 
On the other hand, ME/CFS patients who experienced continued social support 
following illness onset reported deeply valuing those relationships (Clark & James, 
2003). When members of patients’ social networks understood that ME/CFS was 
seriously impacting their functional abilities, trust was increased in those relationships 
(Fisher & Crawley, 2012). 
Illness invalidation from family. In qualitative research, patients reported that 
few of their family members continued to support them and to validate their illness 
(Clarke & James, 2003). Invalidation of illness experiences by a spouse were 
considered particularly emotionally difficult (Dickson et al., 2007) and were negatively 
related to adaptive outcomes (Heijmans, DeRidder, & Bensing, 1999). As one patient 
described it, 
The difference with friends – if they’re not helpful you don’t have to talk to 
them, but with [family] you have to – you can’t choose your family. So you 
learn what to say and what not to say. (Clarke & James, 2003, p. 1391).  
Shame 
Shame has been defined as an individual’s global assessment of the self as 
inferior, deficient, and of diminished value (Woien, Ernst, Patock-Peckham, & Nagoshi, 
2003). Shame has been conceptualized as an emotional response that originates from 
interpersonal transactions (Tangney, Miller, Flicker, & Hill Barlow, 1996), evaluative 
social conditions, and threats to the social self (Dickerson, Gruenwald, & Kenemy, 
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2004; Dickerson, Gruenwald, & Kemeny, 2009). Shame is particularly likely to be 
evoked in situations in which a component of one’s identity is, or has potential to be, 
negatively evaluated by others (Dickerson et al., 2004).  
While shame is considered a negative evaluation of oneself, it is believed to be 
linked to the social environment or to the belief that a critical “imagined other” is 
judging the self (Lewis, 1971). Cooley (1902) explained this as follows, “…there is no 
sense of ‘I,’ in pride or shame, without its correlative sense of you, or he, or they” (p. 
182). As Dickerson and colleagues (2004) described it, “…shame results when 
perceptions of negative social evaluation are transformed into negative self-evaluation” 
(p. 1195).  
Shame has also been conceptualized as an emotional response to low social 
standing and the associated risks of interpersonal rejection, exclusion, or maltreatment 
(Balsamo et al., 2014; Dickerson et al., 2004). Research found that, among psychology 
students, a strong positive correlation existed between blaming oneself for having been 
socially criticized or “put-down” and experience of shame (Gilbert & Miles, 2000, p. 
768). Furthermore, social rank and experiences of shame have been found to be highly 
correlated (Cheung, Gilbert, & Irons, 2004).  
The social aspect of shame has been reflected in qualitative research, as well. In 
a study consisting of nearly one hundred autobiographical narratives, results revealed 
that, in situations in which participants wrote shameful statements, the participants’ 
writing focused upon how others might be negatively evaluating them (Silfver, 2007). 
Shame and Illness. Across history, there has been a social tendency to treat 
individuals with health problems as deficient or blame-worthy (Hodgkins & Baility). 
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One hypothesized motivation for this is that individuals with health difficulties serve as 
“reminders” to healthy individuals of “the dead body" and, as such, [are] repressed and 
repulsed” (p. 226). In Leviticus 21:16-24 of The Bible, individuals with health 
difficulties were relegated to an equivalent status as prostitutes and were classified 
within society as being unclean (Stiker, 1999). Hodgkins and Baility (2009) noted that 
“the dominant view of the disabled body [is] as a natural tragedy, rather than as a matter 
of political oppression and human diversity” (p. 214).  
Anthropologists have noted that Western culture has embraced explanatory 
models of illness that are “blame focused” and that place responsibility for diseases and 
their outcomes upon the patients themselves, often ignoring the complexities of disease 
processes (Finerman & Bennett, 1995, p.1). These attributions of patient responsibilities 
for their illnesses may stem from increased lay and professional education about 
connections between lifestyle choices and disease. Such attributions ignore the reality 
that health difficulties are often induced by multiple causes and are frequently complex. 
However, the emphasis on patient accountability for lifestyle choices may translate into 
interpretations of sick individuals as blameworthy for their illnesses. 
An example of this phenomenon of focusing blame on patients for their illness, 
while ignoring complexities of diseases processes, is reflected in results from qualitative 
research in the United Kingdom. Research there found that individuals with lung cancer 
who had no prior history of smoking considered themselves as being unfairly blamed by 
those around them for their disease (Chapple, Ziebland, & McPherson, 2004). 
Furthermore, some patients noted belief that media reports linking smoking to lung 
cancer may have contributed to the assessment that they were to blame for their cancer. 
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Shame has also been found to negatively correlate with psychological wellbeing, 
and this finding has been found to sustain across the lifespan (Orth, Robins, & Soto, 
2010). Individuals living in Greece who were ashamed of past experiences of physical 
pain were found to have higher levels of psychopathology than individuals who had not 
experienced shame surrounding physical pain (Paschou, Damigos, Mavreas, & Gouva, 
2010). Additionally, external shame (shame stemming from negative evaluations by 
others) has been found to correlate with experiences of depression and with submissive 
behaviors (Cheung et al., 2004; Kim, Thibodeau, & Jorgensen, 2011).  
Research also indicates possible gender differences in external shame. To 
illustrate, women have been found to score higher on measures of external shame than 
men (Cheung et al., 2004; Orth et al., 2010).  
Illness Invalidation and Shame 
Discussing one’s illness within the context of an invalidating environment may 
lead to internalized shame (Myers, 2004). Ware (1992) proposed that, when the 
subjective experience of one’s illness is denied by the social context, shame of “being 
wrong in one’s definition of reality” may occur (p. 347). Indeed, women with ME/CFS 
reported experiencing discrepancies between their own definition of their experience 
and the perceptions of their work environment and their physicians (Asbring & 
Narvanen, 2001).  
Individuals with ME/CFS have expressed feelings of shame associated with 
illness invalidation and of experiencing their identity as questioned and no longer 
legitimate (Larun & Malterud, 2007). In qualitative research, participants sometimes 
related this experience to physicians, other individuals, and members of the media, 
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expressing the belief that ME/CFS was “all in their heads” (Clarke & James, 2003, p. 
1390). Some individuals with ME/CFS even reported removing themselves from their 
former social lives out of feelings of shame over how others perceived them or after 
having others reject that their illness was legitimate (Clarke & James, 2003). 
Social Support and the Stress Buffering Model 
The Stress Buffering Model proposes that social support mitigates the negative 
effects of stress and promotes wellbeing (Cohen & Wills, 1985). Social support is 
conceptualized as manifesting across four support domains. Esteem support refers to 
communication that the individual is valued, worthy, and accepted. Informational 
support is operationalized as provision of coping support, advice, and guidance. Social 
companionship refers to time spent with others that is accompanied by a sense of 
belonging. Finally, instrumental support refers to assistance with tangible needs.   
According to the Stress Buffering Model, esteem support counteracts threats to 
self-concept that may occur during stressful periods by communicating valuing and 
acceptance (Cohen & Wills, 1985). Informational support may promote cognitive 
reappraisals of stressful situations and/or may contribute to successful coping strategies. 
On the other hand, instrumental support and social companionship meet practical and 
affiliation needs during taxing times.  
Numerous research studies appear to support the Stress Buffering Model, with 
evidence of the emotional benefits of social support to patients with health concerns 
indicated across multiple studies. Among individuals with rheumatic diseases, social 
support has been found to significantly relate to improved mental health (Kool et al., 
2012). Specifically, individuals with rheumatoid arthritis who received higher amounts 
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of daily emotional support were more likely to report increased psychological 
wellbeing, decreased anxiety, fewer sleep difficulties, and less depression (Demange et 
al., 2004). Similar results among individuals with advanced cancer in Spain, revealed a 
significant moderate positive correlation between perceived social support and having a 
positive focus (Zabalegui, Cabrera, Navarro, & Cebria, 2011). Among survivors of 
hematopoietic stem cell transplant, emotional and instrumental social support predicted 
posttraumatic growth (Nenova, DuHamel, Zemon, Rini, & Redd, 2013). Furthermore, 
in a study of patients with HIV in Nepal, global satisfaction with social support 
significantly predicted quality of life, with the mediating effect of social support being 
hope (Yadav, 2010). A Japanese study discovered a significant buffering effect of social 
support on depressive symptoms, but the effect was found only in males, and not in 
females (Takizawa et al., 2006).   
Social support has also been linked to health-related quality of life, as well. A 
literature review of 175 studies of social support and coping among prostate cancer 
patients revealed that the preponderance of research has indicated that perception of 
social support exerts a main effect upon health-related quality of life (Paterson, Jones, 
Rattray, & Lauder, 2013). Social support has also been linked to health-related quality 
of life in patients with heart failure (Bakan & Akyol, 2008). In addition, global 
satisfaction with social support predicted health-related quality of life among heart 
transplant recipients at five years post-transplant, and satisfaction with emotional 
aspects of social support predicted health-related quality of life at ten years post heart 
transplant (White-Williams et al., 2013). Among patients with diabetes in Turkey, 
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perceived social support was positively correlated with quality of life as well (Goz, 
Karaoz, Goz, Ekiz, & Cetin, 2007). 
Individuals who lack medical explanations of illness symptoms have reported 
experiencing isolation and lack of social support (Nettleton, 2006). Patients with 
ME/CFS have expressed feelings of loneliness and separation from others, following 
perceived rejection by friends and significant others (Dickson et al., 2007), and 
adolescents with ME/CFS have noted perceiving that their inability to engage in 
activities as before had tested their relationships (Fisher & Crawley, 2012). Many 
patients with ME/CFS noted belief that receiving social support and validation would 
have increased their quality of life and facilitated coping (Dickson et al., 2007). 
However, research on the ameliorative impact of social support among individuals with 
ME/CFS has been limited, further justifying the current study. 
Illness Invalidation, Shame, and the Stress Buffering Model 
Discussing one’s illness within the context of an invalidating environment may 
lead to internalized shame (Myers, 2004). Indeed, individuals with ME/CFS have 
expressed feelings of shame associated with the invalidation of their symptoms and 
having their experiences discounted, minimized, or dismissed (Larun & Malterud, 
2007). According to the Stress Buffering Model, esteem support from social connection 
may help counteract threats to self-concept that may occur during stressful periods by 
communicating valuing and acceptance (Cohen & Wills, 1985). Thus, the following 
research questions appear worthy of investigation. 
Research Questions 
This study will seek to ascertain the following: 
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1) Is there a relationship between illness invalidation and shame among 
ME/CFS sufferers? 
2) Does social support moderate the relationship between illness invalidation 
and shame among ME/CFS sufferers?  
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Chapter Three 
Method 
Participants 
Participants will be 300 adults who suffer from ME/CFS and who are not 
pregnant. Participants will be recruited via ME/CFS and chronic illness support web 
sites, web sites of ME/CFS advocacy and research organizations, and social networking 
sites. 
Instruments 
Demographic information. Demographic information will be requested of 
participants, including information regarding gender, marital status, parenting status, 
income, sexual orientation, ethnicity, and highest level of education attained. 
Participants will also be asked questions pertaining to time since ME/CFS symptom 
onset and time since diagnosis.   
Illness Invalidation Inventory. The Illness Invalidation Inventory (I*3; Kool et 
al., 2010) appears to be the only self-report instrument available, to date, that 
specifically measures perceived illness invalidation. The I*3 is a 40-item self-report 
measure that assesses perceived illness invalidation from five sources: spouse, family, 
medical professionals, work environment, and social services. Each subscale contains 
eight statements, rated on a 5-point Likert scale (ranging from “never” to “very often”). 
Twenty-four items are reverse scored.  
The structure of illness invalidation was established by employing a pilot study 
in which adult patients with fibromyalgia were interviewed regarding their everyday 
experiences of illness invalidation (Kool, Middendorp, Boeije, & Geenen, 2009). Semi-
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structured interviews, utilizing open-ended questions followed by probes, were 
conducted until no new themes emerged across two consecutive interviews. Interviews 
were then transcribed to identify statements regarding illness invalidation. Four 
members of the research team independently evaluated the statements, according to the 
following criteria: (a) statements not made by at least two participants were removed; 
(b) statement that were vague, abstract, or were not generalizable to other patients were 
deleted; and, (c) statements were edited for language and grammar, while retaining the 
participants’ meaning. Participants then performed two separate Q-sort tasks of the 94 
statements. Mean scores were calculated for each statement, in order to rate how 
characteristic each statement was of illness invalidation. A hierarchical cluster analysis 
revealed two higher-order aspects of illness invalidation, namely discounting and 
understanding, and 15 lower-order clusters.  
In construction of the I*3, 45 of the most characteristic statements from the pilot 
study (three statements from each of the 15 lower-order components) were evaluated, 
including scoring and commenting, by thirty patients with rheumatic diseases (Kool et 
al., 2010). Additionally, participants identified the five sources of 
validation/invalidation that they considered most important to them, namely: spouses, 
family, medical professionals, work environments, and social services. Items for the 
instrument were selected according to the following criteria: (a) only one item for each 
original cluster; (b) factor loading of greater than 0.45 following factor analysis; and, 
(c) items should be applicable to all five sources. Eight items met these criteria and 
were utilized in the final instrument. 
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In factor analysis, I*3 statements were found to load on two factors of 
invalidation: Discounting and Lack of Understanding (Kool et al., 2010). A sample 
“Discounting” item is “ My….finds it odd that I can do much more on some days than 
on other days.” An example of a “Lack of Understanding” item is “My….takes me 
seriously” (R). Cronbach’s alphas for both Discounting and Lack of Understanding 
subscales were found to be > .83 in a large New Zealand sample of individuals with 
rheumatic diseases.  
For the purposes of this study, the total score for each individual will be utilized 
in data analyses as an indicator of global experience of illness invalidation. 
 The State Shame and Guilt Scale. Measures of shame fall into two categories: 
(1) those that assess trait shame, and (2) those that measure state shame (Robins, 
Noftle, & Tracy, 2007). Measures of trait shame assess one’s shame-proneness as an 
enduring aspect of the personality. Measures of state shame, on the other hand, assess 
whether one experiences shame at a certain point in time, and such instruments may be 
used to measure shame in response to situational factors. For the purposes of this study, 
it was preferable that shame be measured in regard to one’s experiences of perceived 
illness invalidation, rather than in regard to one’s personality. As a result, the State 
Shame and Guilt Scale (SSGS; Marschall, Sanftner, & Tangney, 1994), a measure of 
state shame, was selected. 
The State Shame and Guilt Scale (Marschall et al., 1994) was originally 
designed as a manipulation check of the initiation of shame in an experimental study of 
shame and empathy (Marschall, 1996). The SSGS is a 15-item (five items in each of 
three subscales) self-report instrument developed to measure Shame (the self as 
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intrinsically bad), Guilt (the self as having behaved poorly), and Pride (the self as 
valued; Marschall et al., 1994). Subscale items were reportedly developed in light of 
empirical and theoretical literature (Dearing & Tangney, 2002). Sample items include, 
“I feel worthwhile, valuable;” “I feel small;” and, “I feel worthless, powerless” 
(Marschall et al., 1994). Participants indicate their agreement/disagreement with 
statements on a five-point Likert scale. All items are scored in a positive direction. 
Subscale reliability coefficients ranged from .82 to .89 in a large sample of 
undergraduate students from an east-coast university. For the purpose of the current 
study, only the Shame subscale scores will be utilized in data analyses.  
 The Medical Outcomes Study Social Support Survey. The Medical Outcomes 
Study Social Support Survey (MOS; Sherbourne & Stewart, 1991) is a 19-item self-
report measure of social support that was designed specifically for use with patients 
with chronic illness. The MOS includes four subscales that measure various dimensions 
of social support; namely, emotional/informational, tangible, affectionate, and positive 
social interactions. For each item, participants rate the availability of that particular 
support on a 5-point Likert scale, ranging from “None of the Time” to “All of the 
Time.” Example items include: “Someone to confide in or talk to about yourself or your 
problems…;” “Someone to share your most private worries and fears…;” and, 
“Someone who understands your problems….” All items are scored in a positive 
direction. 
 In developing the MOS, Sherbourne and Stewart (1991) generated 50 potential 
items based upon a review of existing measures of social support and in light of the 
Social Buffering Hypothesis (Cohen & Wills, 1985) and current theory of social support 
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outlined in existing literature. Items were drafted to measure multiple dimensions of 
support, to be as comprehensive as feasible, and to be concise enough to limit 
participant fatigue. In order to minimize participant burden, social support was 
measured without respect for the source (e.g., whether social support came from friends, 
community, religious circles, etc.). Items were designed to distinctly differentiate from 
similar measures of loneliness, emotional health, family functioning, and limitations on 
social activity. 
 In order to assess face validity of the MOS, six behavioral scientists assigned 
each item to a social support category. Items that were difficult to categorize were 
discarded (Sherbourne & Stewart, 1991). The remaining thirty-eight items were utilized 
in a pilot study with patients at a rural medical clinic in Southern Illinois. Items that 
were not internally consistent with their hypothesized dimension of social support and 
that did not discriminate between social support and other aspects of health and health-
related behavior were eliminated, resulting in the final instrument consisting of 19 
items. Items were hypothesized to measure the following dimensions of social support: 
(a) emotional support (expression of positive feelings, empathy, understanding, and 
encouragement of expression of emotion); (b) informational support (offering 
suggestions, guidance, information, or feedback); (c) tangible support (providing 
material or physical assistance); (d) positive social interactions (providing enjoyable 
experiences and activities); and, (e) affectionate support (expression of positive regard, 
fondness, and love).    
 In order to evaluate the psychometric properties of the MOS, a large sample of 
patients (N = 2,987) from three research sites (Boston, Chicago, and Los Angeles) and 
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from three different healthcare systems (health maintenance organizations, large 
multispecialty groups, and private fee-for-service practice) completed the measure 
(Sherbourne & Stewart, 1991). In order to establish discriminant validity of social 
support items and to evaluate the construct validity of the MOS, participants also 
completed numerous health and wellbeing instruments.  
 Because multitrait scaling revealed notable overlap between emotional support 
and informational support items in the MOS, these items were combined into a single 
emotional/informational subscale (Sherbourne & Stewart, 1991). All items evidenced 
high correlation with their hypothesized subscales (r ≥ .72), surpassing convergent 
validity criterion of r = .30. Item-subscale correlations ranged from r = .72 to .90. 
Internal-consistency reliability was high for each subscale, with alphas ranging from .91 
to .97, and one-year stability coefficients ranged from .72 to .78. 
 All items in the four subscales of the MOS evidenced discriminant validity 
(Sherbourne & Stewart, 1991). Additionally, items were found to discriminate from 
measures of loneliness, mental health, feelings of belonging, perceptions of current 
health, and other dimensions of family and interpersonal functioning. The MOS 
subscales were found to be highly correlated (r = .69 - .82), as might be anticipated if 
they measure dimensions of the shared higher order factor of social support. However, 
multitrait and confirmatory factor analyses supported the use of subscales for scoring. 
Further, the authors recommended utilization of subscale scores in research, based upon 
their usefulness in testing theoretical hypotheses. Therefore, the current study will 
utilize combined scores from the emotional/information support subscale and the 
affectionate support subscale, as these subscales seem to best represent the construct of 
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esteem support (i.e., communication that the individual is valued, worthy, and 
accepted), as outlined in the Stress Buffering Model (Cohen & Wills, 1985).  
Procedure 
University of Oklahoma Institutional Review Board review and approval will be 
obtained prior to commencing this study. A snowball convenience sampling method 
will be utilized. An online survey will be created via Qualtrics, and will be maintained 
via a secure server in University of Oklahoma’s Center for Educational Development 
and Research. Links to the study will be posted on ME/CFS and chronic illness support 
web sites, web sites of ME/CFS advocacy and research organizations, and social 
networking sites. Participation will be voluntary, without remuneration. Following 
consent, participants may skip questions or exit the survey at any time. No identifying 
information will be collected. Contacts and participants will be encouraged to forward 
the link to other adults with ME/CFS.  
Hypotheses 
 It is hypothesized that there will be a positive and significant relationship 
between illness invalidation (I*3) and shame (SSGS). It is further hypothesized that 
social support (MOS) will moderate the relationship between illness invalidation and 
shame, with increases in social support leading to decreases in shame.  
Statistical Analyses 
A hierarchical regression model will be utilized to evaluate the hypotheses.  
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Appendix A 
Illness Invalidation Inventory (3*I) 
 
© 2008, Kool, van Middendorp & Geenen 
 
We are interested in how others react to people who have health problems or an illness. 
Each of the sections below refers to different people in your life. We would like you to 
rate how often during the past year each person or category of people reacted toward 
you in the way described. After each statement, circle the number between 1 (never) 
and 5 (very often) to indicate how often they reacted toward you that way. 
 
The questionnaire has five sections, and you will rate the same reactions a number of 
times, but referring to different people. If a particular section does not apply to you, you 
may skip that part of the questionnaire and go on to the next section. Remember, rate 
the items with respect to how others reacted toward you as a person who has health 
problems or an illness. 
Section 1: Spouse or partner    
 
If you are single (not married, a widow/widower, or without a steady partner) then skip 
Section 1 and go directly to Section 2. 
My spouse or partner…………… Never Seldom 
Some-
times 
Often 
Very 
often 
1.1 ….finds it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
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1.2 ….thinks I should be tougher. 1 2 3 4 5 
1.3 ….takes me seriously. 1 2 3 4 5 
1.4 ….gives me unhelpful advice. 1 2 3 4 5 
1.5 ….understands the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
1.6 ….makes me feel like I am an 
exaggerator. 
 
1 2 3 4 5 
1.7 ….thinks I can work more than I do. 1 2 3 4 5 
1.8 ….gives me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
 
Section 2: Family 
For example, children, parents, brothers, sisters, uncles, aunts, grandparents, in-laws. 
 
My family……… Never Seldom 
Some-
times 
Often 
Very 
often 
2.1 ….finds it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
2.2 ….thinks I should be tougher. 1 2 3 4 5 
2.3 ….takes me seriously. 1 2 3 4 5 
2.4 ….gives me unhelpful advice. 1 2 3 4 5 
2.5 ….understands the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
2.6 ….makes me feel like I am an 
exaggerator. 
 
1 2 3 4 5 
2.7 ….thinks I can work more than I do. 1 2 3 4 5 
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2.8 ….gives me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
 
Section 3: Medical professionals  
For example, your primary care physician, medical specialist, physical therapist, and 
other medical professionals. (Do not include your employer’s company physician). 
  
Medical professionals ..... Never Seldom 
Some-
times 
Often 
Very 
often 
3.1 ….find it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
3.2 ….think I should be tougher. 1 2 3 4 5 
3.3 ….take me seriously. 1 2 3 4 5 
3.4 ….give me unhelpful advice. 1 2 3 4 5 
3.5 ….understand the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
3.6 ….make me feel like I am an 
exaggerator. 
 
1 2 3 4 5 
3.7 ….think I can work more than I do. 1 2 3 4 5 
3.8 ….give me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
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If you did not have paid or unpaid employment in the past year, then skip this Section and 
go directly to Section 5. 
People at work…….  Never Seldom 
Some-
times 
Often 
Very 
often 
4.1 ….find it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
4.2 ….think I should be tougher. 1 2 3 4 5 
4.3 ….take me seriously. 1 2 3 4 5 
4.4 ….give me unhelpful advice. 1 2 3 4 5 
4.5 ….understand the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
4.6 ….makes me feel like I am an 
exaggerator. 
 
1 2 3 4 5 
4.7 ….think I can work more than I do. 1 2 3 4 5 
4.8 ….give me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
 
 
 
 
 
 
 
Section 4:  Work environment   
For example, your co-workers and boss. (Do not include your employer’s company 
physician).  
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If you did not have any interactions with these providers, you may skip this Section.  
People in social services…….  Never Seldom 
Some-
times 
Often 
Very 
often 
5.1 ….find it odd that I can do much 
more on some days than on other 
days. 
1 2 3 4 5 
5.2 ….think I should be tougher. 1 2 3 4 5 
5.3 ….take me seriously. 1 2 3 4 5 
5.4 ….give me unhelpful advice. 1 2 3 4 5 
5.5 ….understand the consequences of 
my health problems or illness. 
 
1 2 3 4 5 
5.6 ….make me feel like I am an 
exaggerator. 
 
1 2 3 4 5 
5.7 ….think I can work more than I do. 1 2 3 4 5 
5.8 ….give me the chance to talk about 
what is on my mind. 
1 2 3 4 5 
 
 
 
 
 
 
 
Section 5 : Social services  
For example, your employer’s company physician, work-reintegration or vocational 
rehabilitation staff, unemployment and other government agencies, organizations for 
care at home, general government workers and health insurance companies. 
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Appendix B 
The State Shame and Guilt Scale 
(Marschall, Sanftner, & Tangney, 1994) 
 
The following are some statements which may or may not describe how you are feeling 
right now.  Please rate each statement using the 5-point scale below.  Remember to rate 
each statement based on how you are feeling right at this moment. 
 
  
                                        Not feeling        Feeling          Feeling          
                                            this way           this way         this way 
                                              at all          somewhat     very strongly 
 
1.  I feel good about myself. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
2.  I want to sink into the floor and disappear. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
4. I feel remorse, regret. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
4.  I feel worthwhile, valuable. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
5.  I feel small. 1 ------- 2 ------- 3 ------- 4 ------- 5 
 
6.  I feel tension about something I have done. 1 ------- 2 ------- 3 ------- 4 ------- 5 
7.  I feel capable, useful. 1 ------- 2 ------- 3 ------- 4 ------- 5 
8.  I feel like I am a bad person. 1 ------- 2 ------- 3 ------- 4 ------- 5 
10. I cannot stop thinking about something  
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      bad I have done. 1 ------- 2 ------- 3 ------- 4 ------- 5 
10. I feel proud. 1 ------- 2 ------- 3 ------- 4 ------- 5 
11. I feel humiliated, disgraced. 1 ------- 2 ------- 3 ------- 4 ------- 5 
12. I feel like apologizing, confessing. 1 ------- 2 ------- 3 ------- 4 ------- 5 
13. I feel pleased about something I have done. 1 ------- 2 ------- 3 ------- 4 ------- 5 
14. I feel worthless, powerless.  1 ------- 2 ------- 3 ------- 4 ------- 5 
15. I feel bad about something I have done.  1 ------- 2 ------- 3 ------- 4 ------- 5
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Appendix C 
MOS Social Support Survey 
(Sherbourne & Stewart, 1991) 
 
Next are some questions about the support that is available to you. 
 
People sometimes look to others for companionship, assistance, or other types of 
support. How often is each of the following kinds of support available to you if you 
need it?  
 
None of the time    A little of the time    Some of the time    Most of the time    All of the time 
1        2      3   4      5 
 
20) Someone to help you if you were confined to bed…. 
21) Someone you can count on to listen to you when you need to talk…. 
22) Someone to give you good advice about a crisis…. 
23) Someone to take you to the doctor if you needed it…. 
24) Someone who shows you love and affection…. 
25) Someone to have a good time with…. 
26) Someone to give you information to help you understand a situation…. 
27) Someone to confide in or talk to about yourself or your problems…. 
28) Someone who hugs you…. 
29) Someone to get together with for relaxation…. 
30) Someone to prepare your meals if you were unable to do it yourself…. 
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31) Someone whose advice you really want…. 
32) Someone to do things with to help you get your mind off things…. 
33) Someone to help with daily chores if you were sick…. 
34) Someone to share your most private worries and fears with…. 
35) Someone to turn to for suggestions about how to deal with a personal 
problem…. 
36) Someone to do something enjoyable with…. 
37) Someone who understands your problems…. 
38) Someone to love and make you feel wanted…. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
